Calcineurin	B-protein
potentiates	O
activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
:	O
involvement	O
of	O
the	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
.	O

Granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
leukemia	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
GM-CSF	B-protein
and	O
IL-2	B-protein
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	B-protein
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
through	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	B-DNA
for	O
CN	B-protein
A	I-protein
(	I-protein
catalytic	I-protein
)	I-protein
and	I-protein
CN	I-protein
B	I-protein
(	I-protein
regulatory	I-protein
)	I-protein
subunits	I-protein
also	O
augments	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	B-protein
A	I-protein
subunit	I-protein
,	O
which	O
lacks	O
the	O
auto-inhibitory	B-protein
and	O
calmodulin-binding	B-protein
domains	I-protein
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	B-protein
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM-CSF	B-protein
and	O
IL-2	B-protein
.	O

By	O
multimerizing	O
the	O
regulatory	B-DNA
elements	I-DNA
of	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	B-DNA
sites	I-DNA
for	O
the	O
CN	B-protein
action	O
is	O
the	O
conserved	B-DNA
lymphokine	I-DNA
element	I-DNA
0	I-DNA
(	O
CLE0	B-DNA
)	O
,	O
located	O
at	O
positions	O
between	O
-54	O
and	O
-40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	B-DNA
sequence	O
has	O
an	O
AP1-binding	B-DNA
site	I-DNA
and	O
is	O
associated	O
with	O
an	O
NF-AT-like	B-protein
factor	I-protein
,	O
termed	O
NF-CLE0	B-protein
gamma	I-protein
.	O

NF-	O
CLE0	B-DNA
gamma	O
binding	O
is	O
induced	O
by	O
PMA/A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	B-protein
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM-CSF	B-DNA
and	I-DNA
IL-2	I-DNA
genes	I-DNA
and	O
that	O
the	O
CLE0	B-DNA
sequence	I-DNA
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF-AT-binding	B-DNA
site	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL
Vol	NULL
.	NULL

5	NULL
,	NULL
119-128	NULL
,	NULL
January	NULL
1994	NULL
Calcineurin	NULL
Potentiates	NULL
Activation	NULL
of	NULL
the	NULL
Granulocyte-Macrophage	NULL
Colony-stimulating	NULL
Factor	NULL
Gene	NULL
in	NULL
T	NULL
Cells	NULL
:	NULL
Involvement	NULL
of	NULL
the	NULL
Conserved	NULL
Lymphokine	NULL
Element	NULL
0	NULL
Akio	NULL
Tsuboi	NULL
,	NULL
*	NULL
Esteban	NULL
S.	NULL
Masuda	NULL
,	NULL
*	NULL
Yoshiyuki	NULL
Naito	NULL
,	NULL
*	NULL
Hiroshi	NULL
Tokumitsu	NULL
,	NULL
*	NULL
Ken-ichi	NULL
Arai	NULL
,	NULL
t	NULL
and	NULL
Naoko	NULL
Arai*t	NULL
*Department	NULL
of	NULL
Molecular	NULL
Biology	NULL
,	NULL
DNAX	NULL
Research	NULL
Institute	NULL
of	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
California	NULL
94304-1104	NULL
;	NULL
and	NULL
{	NULL
Department	NULL
of	NULL
Molecular	NULL
and	NULL
Developmental	NULL
Biology	NULL
,	NULL
Institute	NULL
of	NULL
Medical	NULL
Science	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Tokyo	NULL
,	NULL
Tokyo	NULL
108	NULL
,	NULL
Japan	NULL
Submitted	NULL
August	NULL
30	NULL
,	NULL
1993	NULL
;	NULL
Accepted	NULL
December	NULL
6	NULL
,	NULL
1993	NULL
Monitoring	NULL
Editor	NULL
:	NULL
Timothy	NULL
A.	NULL
Springer	NULL
Granulocyte-macrophage	NULL
colony	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
are	NULL
produced	NULL
by	NULL
stimulation	NULL
with	NULL
phorbol-12-myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
calcium	NULL
ionophore	NULL
(	NULL
A23187	NULL
)	NULL
in	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
is	NULL
inhibited	NULL
by	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
.	NULL

Earlier	NULL
studies	NULL
on	NULL
the	NULL
IL-2	NULL
gene	NULL
expression	NULL
showed	NULL
that	NULL
overexpression	NULL
of	NULL
calcineurin	NULL
(	NULL
CN	NULL
)	NULL
,	NULL
a	NULL
Ca**	NULL
/calmodulin-dependent	NULL
protein	NULL
phosphatase	NULL
,	NULL
can	NULL
stimulate	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
through	NULL
the	NULL
NF-AT-binding	NULL
site	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
obtained	NULL
evidence	NULL
that	NULL
transfection	NULL
of	NULL
the	NULL
cDNAs	NULL
for	NULL
CN	NULL
A	NULL
(	NULL
catalytic	NULL
)	NULL
and	NULL
CN	NULL
B	NULL
(	NULL
regulatory	NULL
)	NULL
subunits	NULL
also	NULL
augments	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
and	NULL
recovers	NULL
the	NULL
transcription	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

The	NULL
constitutively	NULL
active	NULL
type	NULL
of	NULL
the	NULL
CN	NULL
A	NULL
subunit	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
auto-inhibitory	NULL
and	NULL
calmodulin-binding	NULL
domains	NULL
,	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
the	NULL
active	NULL
CN	NULL
partially	NULL
replaces	NULL
calcium	NULL
ionophore	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
expression	NULL
of	NULL
endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
.	NULL

By	NULL
multi-merizing	NULL
the	NULL
regulatory	NULL
elements	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
we	NULL
found	NULL
that	NULL
one	NULL
of	NULL
the	NULL
target	NULL
sites	NULL
for	NULL
the	NULL
CN	NULL
action	NULL
is	NULL
the	NULL
conserved	NULL
lymphokine	NULL
element	NULL
0	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
located	NULL
at	NULL
positions	NULL
between	NULL
-54	NULL
and	NULL
-40	NULL
.	NULL

Mobility	NULL
shift	NULL
assays	NULL
showed	NULL
that	NULL
the	NULL
CLEO	NULL
sequence	NULL
has	NULL
an	NULL
AP1-binding	NULL
site	NULL
and	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
NF-AT-like	NULL
factor	NULL
,	NULL
termed	NULL
NF-CLEO	NULL
y.	NULL
NF-CLEO	NULL
y	NULL
binding	NULL
is	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
and	NULL
is	NULL
inhibited	NULL
by	NULL
treatment	NULL
with	NULL
CsA	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
CN	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
coordinated	NULL
induction	NULL
of	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
genes	NULL
and	NULL
that	NULL
the	NULL
CLEO	NULL
sequence	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
is	NULL
a	NULL
functional	NULL
analogue	NULL
of	NULL
the	NULL
NF-AT-binding	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
which	NULL
mediates	NULL
signals	NULL
downstream	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

INTRODUCTION	NULL
Activation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
recognition	NULL
of	NULL
antigens	NULL
on	NULL
an-tigen-presenting	NULL
cells	NULL
leads	NULL
to	NULL
induction	NULL
of	NULL
nuclear	NULL
proto-oncogenes	NULL
such	NULL
as	NULL
c-fos	NULL
in	NULL
15	NULL
to	NULL
30	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
induction	NULL
of	NULL
a	NULL
battery	NULL
of	NULL
lymphokine	NULL
genes	NULL
,	NULL
including	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
genes	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Upon	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
one	NULL
{	NULL
Corresponding	NULL
author	NULL
.	NULL

Â©	NULL
1994	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Cell	NULL
Biology	NULL
of	NULL
the	NULL
major	NULL
events	NULL
is	NULL
hydrolysis	NULL
of	NULL
phosphatidylino-sitol-4,5-biphosphate	NULL
to	NULL
generate	NULL
inositol-1,4,5-tri-phosphate	NULL
(	NULL
IP	NULL
;	NULL
)	NULL
and	NULL
diacylglycerol	NULL
(	NULL
DG	NULL
)	NULL
by	NULL
phospho-lipase	NULL
C	NULL
(	NULL
Berridge	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

IP	NULL
;	NULL
raises	NULL
the	NULL
cytoplasmic	NULL
Ca**	NULL
concentration	NULL
from	NULL
sequestered	NULL
intracellular	NULL
stores	NULL
,	NULL
thereby	NULL
opening	NULL
Ca**	NULL
channels	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
(	NULL
Berridge	NULL
,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
process	NULL
can	NULL
be	NULL
functionally	NULL
mimicked	NULL
by	NULL
a	NULL
Ca**	NULL
ionophore	NULL
such	NULL
as	NULL
A23187	NULL
.	NULL

DG	NULL
together	NULL
with	NULL
Ca**	NULL
activates	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
and	NULL
phorbol	NULL
esters	NULL
such	NULL
as	NULL
phorbol-12-myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
can	NULL
mimic	NULL
the	NULL
effect	NULL
of	NULL
DG	NULL
.	NULL

Stimulation	NULL
with	NULL
PMA	NULL
and	NULL
Ca**	NULL
119	NULL
A.	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

ionophore	NULL
leads	NULL
to	NULL
considerable	NULL
induction	NULL
of	NULL
several	NULL
lymphokine	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
par-ticular	NULL
,	NULL
there	NULL
is	NULL
strong	NULL
synergy	NULL
between	NULL
PKC-	NULL
and	NULL
Ca**-signaling	NULL
pathways	NULL
in	NULL
the	NULL
production	NULL
of	NULL
GM-CSF	NULL
or	NULL
IL-2	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Riegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
is	NULL
inhibited	NULL
by	NULL
immunosuppressive	NULL
drugs	NULL
such	NULL
as	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Riegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
on	NULL
IL-2	NULL
gene	NULL
expression	NULL
revealed	NULL
that	NULL
a	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
transcriptional	NULL
activation	NULL
and	NULL
is	NULL
one	NULL
of	NULL
the	NULL
functional	NULL
targets	NULL
for	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
Riegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

NFE-AT	NULL
appears	NULL
to	NULL
consist	NULL
of	NULL
two	NULL
factors	NULL
:	NULL
one	NULL
is	NULL
a	NULL
ubiquitous	NULL
nuclear	NULL
factor	NULL
(	NULL
NF-AT	NULL
,	NULL
,	NULL
)	NULL
,	NULL
induced	NULL
through	NULL
the	NULL
PKC	NULL
pathway	NULL
and	NULL
identified	NULL
as	NULL
AP-1	NULL
(	NULL
Jun-	NULL
and	NULL
Fos-family	NULL
proteins	NULL
)	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
other	NULL
is	NULL
a	NULL
T	NULL
cell-specific	NULL
,	NULL
pre-existing	NULL
component	NULL
(	NULL
NF-AT	NULL
,	NULL
)	NULL
,	NULL
and	NULL
translocation	NULL
from	NULL
cytoplasm	NULL
to	NULL
nucleus	NULL
is	NULL
regulated	NULL
through	NULL
the	NULL
Ca**	NULL
pathway	NULL
and	NULL
inhibited	NULL
by	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
Flanagan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

These	NULL
drugs	NULL
bind	NULL
endogenous	NULL
intracellular	NULL
receptors	NULL
(	NULL
immunophilins	NULL
)	NULL
and	NULL
the	NULL
resulting	NULL
complexes	NULL
target	NULL
a	NULL
Ca**/calmodulin-dependent	NULL
Ser/	NULL
Thr	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
CN	NULL
)	NULL
,	NULL
to	NULL
exert	NULL
immunosuppressive	NULL
effects	NULL
(	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

CN	NULL
is	NULL
composed	NULL
of	NULL
catalytic	NULL
(	NULL
A	NULL
)	NULL
and	NULL
regulatory	NULL
(	NULL
B	NULL
)	NULL
subunits	NULL
,	NULL
and	NULL
overexpression	NULL
can	NULL
restore	NULL
the	NULL
NF-AT-dependent	NULL
transcription	NULL
inhibited	NULL
by	NULL
CsA	NULL
or	NULL
FK506	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
the	NULL
CN	NULL
A	NULL
subunit	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
activate	NULL
transcription	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
through	NULL
the	NULL
NF-AT-binding	NULL
site	NULL
,	NULL
thereby	NULL
indicating	NULL
that	NULL
expression	NULL
of	NULL
activated	NULL
CN	NULL
can	NULL
mimic	NULL
a	NULL
Ca**	NULL
signaling	NULL
pathway	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

We	NULL
have	NULL
identified	NULL
two	NULL
elements	NULL
,	NULL
GM-	NULL
Â«	NULL
B/GC	NULL
box	NULL
(	NULL
formerly	NULL
GM2/GC	NULL
box	NULL
)	NULL
and	NULL
CLEO	NULL
,	NULL
as	NULL
essential	NULL
cis-elements	NULL
of	NULL
the	NULL
mouse	NULL
GM-CSF	NULL
gene	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988b	NULL
,	NULL
1991	NULL
;	NULL
Heike	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Together	NULL
these	NULL
elements	NULL
are	NULL
responsible	NULL
for	NULL
maximal	NULL
activation	NULL
,	NULL
induced	NULL
by	NULL
costimulation	NULL
with	NULL
PMA/A23187	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988b	NULL
,	NULL
1991	NULL
;	NULL
Heike	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
sequence	NULL
between	NULL
-95	NULL
and	NULL
-73	NULL
contains	NULL
two	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
one	NULL
(	NULL
GGTAGTTCCC	NULL
)	NULL
is	NULL
recognized	NULL
by	NULL
an	NULL
inducible	NULL
factor	NULL
,	NULL
NF-GM2	NULL
and	NULL
the	NULL
other	NULL
(	NULL
CCGCCC	NULL
)	NULL
by	NULL
a	NULL
set	NULL
of	NULL
constitutive	NULL
factors	NULL
,	NULL
A1	NULL
(	NULL
Spl	NULL
)	NULL
,	NULL
A2	NULL
,	NULL
and	NULL
B	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
NF-GM2	NULL
from	NULL
nuclear	NULL
extracts	NULL
of	NULL
PMA/A23187-stimulated	NULL
Jurkat	NULL
cells	NULL
revealed	NULL
that	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
sequence	NULL
is	NULL
recognized	NULL
by	NULL
NF-GM2	NULL
consisting	NULL
of	NULL
50-	NULL
and	NULL
65-kDa	NULL
polypeptides	NULL
which	NULL
are	NULL
immunologically	NULL
indistinguishable	NULL
from	NULL
50-	NULL
and	NULL
65-kDa	NULL
subunits	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
respectively	NULL
(	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
either	NULL
GM-	NULL
Â«	NULL
B	NULL
or	NULL
GC-box	NULL
sequence	NULL
abolish	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
as	NULL
well	NULL
as	NULL
the	NULL
DNA	NULL
binding	NULL
of	NULL
respective	NULL
factors	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
other	NULL
element	NULL
,	NULL
conserved	NULL
lymphokine	NULL
element	NULL
0	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
extends	NULL
from	NULL
-54	NULL
to	NULL
-40	NULL
downstream	NULL
of	NULL
the	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
element	NULL
and	NULL
shares	NULL
strong	NULL
homology	NULL
120	NULL
with	NULL
the	NULL
5'-flanking	NULL
regions	NULL
of	NULL
the	NULL
IL-4	NULL
and	NULL
IL-5	NULL
genes	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Mutations	NULL
in	NULL
the	NULL
CLEO	NULL
element	NULL
fail	NULL
to	NULL
induce	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
gene	NULL
as	NULL
well	NULL
as	NULL
DNA	NULL
binding	NULL
to	NULL
this	NULL
sequence	NULL
in	NULL
response	NULL
to	NULL
PMA/A23187	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

We	NULL
report	NULL
here	NULL
that	NULL
overexpression	NULL
of	NULL
CN	NULL
augments	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
,	NULL
presumably	NULL
through	NULL
the	NULL
CLEO	NULL
element	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
CLEO	NULL
element	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
NF-AT-like	NULL
factor	NULL
,	NULL
whose	NULL
binding	NULL
is	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
and	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
CsA	NULL
.	NULL

The	NULL
coordinated	NULL
regulation	NULL
of	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
genes	NULL
through	NULL
the	NULL
CLEO-like	NULL
element	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
discussed	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture	NULL
and	NULL
Lymphokine	NULL
Assays	NULL
Jurkat	NULL
cells	NULL
(	NULL
a	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
line	NULL
)	NULL
,	NULL
provided	NULL
by	NULL
Dr.	NULL
P.	NULL
Berg	NULL
(	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
JRH	NULL
Biosciences	NULL
)	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
penicillin	NULL
G	NULL
(	NULL
100	NULL
U/m	NULL
!	NULL
)	NULL

,	NULL
and	NULL
streptomycin	NULL
(	NULL
100	NULL
mg/m	NULL
!	NULL
)	NULL

.	NULL

Cells	NULL
at	NULL
a	NULL
density	NULL
of	NULL
2	NULL
X	NULL
10Â°	NULL
cells/ml	NULL
were	NULL
treated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
0-50	NULL
ng/ml	NULL
,	NULL
Calbiochem	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
A23187	NULL
(	NULL
0-2.5	NULL
uM	NULL
,	NULL
Calbiochem	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
Sandimmun	NULL
,	NULL
Sandoz	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
at	NULL
the	NULL
concentration	NULL
of	NULL
0	NULL
to	NULL
1.0	NULL
ug/ml	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
24	NULL
h	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
collected	NULL
by	NULL
centrifugation	NULL
and	NULL
subjected	NULL
to	NULL
ELISA	NULL
for	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
(	NULL
Abrams	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Mobility	NULL
Shift	NULL
Assays	NULL
Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
on	NULL
a	NULL
small	NULL
scale	NULL
,	NULL
basically	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Schreiber	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
after	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
(	NULL
2-5	NULL
x	NULL
10	NULL
``	NULL
)	NULL
with	NULL
50	NULL
ng/ml	NULL
PMA	NULL
,	NULL
1	NULL
uM	NULL
A23187	NULL
,	NULL
or	NULL
both	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1	NULL
ug/ml	NULL
CsA	NULL
for	NULL
2-3	NULL
h	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
binding	NULL
assays	NULL
to	NULL
the	NULL
GC-box	NULL
(	NULL
gm-mu	NULL
7.8	NULL
)	NULL
and	NULL
GM-	NULL
Â«	NULL
B	NULL
(	NULL
gm-mu	NULL
17.18	NULL
)	NULL
sequences	NULL
,	NULL
binding	NULL
reaction	NULL
and	NULL
electrophoresis	NULL
were	NULL
done	NULL
using	NULL
2.5	NULL
ug	NULL
and	NULL
10	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
,	NULL
respectively	NULL
,	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
reaction	NULL
to	NULL
the	NULL
CLEO	NULL
and	NULL
NF-AT	NULL
sequences	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
10	NULL
mM	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
(	NULL
MEPES	NULL
)	NULL
-NaOH	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
(	NULL
DTT	NULL
)	NULL
,	NULL
50	NULL
ug/ml	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Pharmacia	NULL
)	NULL
,	NULL
250	NULL
ug	NULL
/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
~0.5	NULL
ng	NULL
of	NULL
labeled	NULL
probe	NULL
(	NULL
~50	NULL
000	NULL
cpm	NULL
)	NULL
,	NULL
and	NULL
12	NULL
ug	NULL
of	NULL
nuclear	NULL
extracts	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
sample	NULL
was	NULL
applied	NULL
onto	NULL
a	NULL
4	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
a	NULL
tris	NULL
(	NULL
hydroxymethyl	NULL
)	NULL
aminomethane	NULL
(	NULL
Tris	NULL
)	NULL
-glycine-EDTA	NULL
buffer	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
dried	NULL
and	NULL
autoradiographed	NULL
after	NULL
electrophoresis	NULL
at	NULL
120	NULL
V	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Oligonucleotides	NULL
for	NULL
mobility-shift	NULL
and	NULL
competition	NULL
assays	NULL
are	NULL
shown	NULL
below	NULL
as	NULL
one	NULL
strand	NULL
,	NULL
with	NULL
the	NULL
overhang	NULL
in	NULL
lower	NULL
case	NULL
.	NULL

Underlines	NULL
depict	NULL
a	NULL
substitution	NULL
mutation	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

GC-box	NULL
(	NULL
gm-mu	NULL
7.8	NULL
)	NULL
:	NULL
gatcAGGTAGTGCCCCCGCCCCCC	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
GM-	NULL
Â«	NULL
B	NULL
(	NULL
gm-mu	NULL
17.18	NULL
)	NULL
:	NULL
gatcAGGTAGTTCCCCCGCACCCC	NULL
(	NULL
Sugimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
CLEO	NULL
:	NULL
gatecGTCACCATTAATCATTTCCTCTAACTGT	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
NF-AT	NULL
:	NULL
gatcGGAGGAAAAACTGTTTCATACAGAAGGCCGT	NULL
(	NULL
Emme	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
Sp1	NULL
:	NULL
GATCGATCGGGGCGGGGCCGATC	NULL
(	NULL
Dynan	NULL
and	NULL
Tjian	NULL
,	NULL
1983	NULL
)	NULL
Plasmid	NULL
Construction	NULL
All	NULL
plasmids	NULL
were	NULL
constructed	NULL
and	NULL
manipulated	NULL
using	NULL
standard	NULL
techniques	NULL
(	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

All	NULL
DNA	NULL
sequences	NULL
inserted	NULL
into	NULL
vectors	NULL
Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL
were	NULL
confirmed	NULL
by	NULL
the	NULL
dideoxy	NULL
chain	NULL
termination	NULL
method	NULL
using	NULL
Se-quenase	NULL
(	NULL
United	NULL
States	NULL
Biochemicals	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
)	NULL
.	NULL

pIL-2	NULL
CAT-1	NULL
,	NULL
provided	NULL
from	NULL
Dr.	NULL
G.R	NULL
.	NULL

Crabtree	NULL
(	NULL
Stanford	NULL
)	NULL
,	NULL
has	NULL
sequences	NULL
-567	NULL
to	NULL
+47	NULL
from	NULL
the	NULL
human	NULL
IL-2	NULL
gene	NULL
controlling	NULL
expression	NULL
of	NULL
a	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
(	NULL
Siebenlist	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

pIL-2	NULL
Luc-1	NULL
was	NULL
constructed	NULL
by	NULL
replacing	NULL
the	NULL
SRa	NULL
promoter	NULL
(	NULL
HindIII	NULL
fragment	NULL
)	NULL
of	NULL
pSRa-L-AA5	NULL
'	NULL
(	NULL
Takebe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
HindIII	NULL
fragment	NULL
)	NULL
of	NULL
pIL-2	NULL
CAT-1	NULL
.	NULL

pKC1	NULL
carrying	NULL
a	NULL
sequence	NULL
-97	NULL
to	NULL
+27	NULL
of	NULL
the	NULL
mouse	NULL
GM-CSF	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
was	NULL
constructed	NULL
by	NULL
replacing	NULL
the	NULL
Bg/II-BsfEII	NULL
fragment	NULL
of	NULL
pmGMCAT-740	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988b	NULL
)	NULL
with	NULL
synthetic	NULL
oligonucleotides	NULL
(	NULL
N1	NULL
:	NULL
N2	NULL
)	NULL
.	NULL

NI1	NULL
:	NULL
N2	NULL
gatcAACTCAGGTAGTTCCCCCGCCCCCCTGGACTTCTCGTG	NULL
TTGAGTCCATCAAGGGGGCGGGGGCGACCTCAAGA-CACCAGTG	NULL
pKC17	NULL
harboring	NULL
a	NULL
sequence	NULL
-97	NULL
to	NULL
+27	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
luciferase	NULL
gene	NULL
was	NULL
constructed	NULL
by	NULL
replacing	NULL
the	NULL
Ndel-Sacl	NULL
fragment	NULL
of	NULL
pmGMLuc-740	NULL
(	NULL
Heike	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
with	NULL
the	NULL
Ndel-Sacl	NULL
fragment	NULL
of	NULL
pKC1	NULL
.	NULL

p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
,	NULL
CAT	NULL
and	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
CAT	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
were	NULL
constructed	NULL
by	NULL
replacing	NULL
the	NULL
Bg	NULL
!	NULL

lI-Sacl	NULL
fragment	NULL
of	NULL
pmGMCAT-740	NULL
with	NULL
synthetic	NULL
oligonucleotides	NULL
,	NULL
which	NULL
contain	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
GM-	NULL
Â«	NULL
B/	NULL
GC-box	NULL
(	NULL
-91	NULL
to	NULL
-72	NULL
)	NULL
and	NULL
CLEO	NULL
(	NULL
-70	NULL
to	NULL
-37	NULL
)	NULL
sequences	NULL
,	NULL
respectively	NULL
.	NULL

p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
(	NULL
Figure	NULL
6D	NULL
)	NULL
was	NULL
also	NULL
generated	NULL
by	NULL
replacing	NULL
the	NULL
Bgill-Sacl	NULL
fragment	NULL
of	NULL
pmGMCAT-740	NULL
with	NULL
synthetic	NULL
oligonucleotides	NULL
,	NULL
which	NULL
contain	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
CLEO	NULL
sequence	NULL
-57	NULL
to	NULL
-37	NULL
linked	NULL
by	NULL
Bgill	NULL
and	NULL
Secl	NULL
overhangs	NULL
.	NULL

pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
,	NULL
provided	NULL
by	NULL
Dr.	NULL
N.A	NULL
.	NULL

Clipstone	NULL
(	NULL
Stanford	NULL
)	NULL
,	NULL
contain	NULL
murine	NULL
cDNAs	NULL
for	NULL
the	NULL
A	NULL
,	NULL
,	NULL
;	NULL
and	NULL
B	NULL
subunits	NULL
of	NULL
CN	NULL
,	NULL
respectively	NULL
,	NULL
under	NULL
control	NULL
of	NULL
the	NULL
SRa	NULL
promoter	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

A	NULL
deletion	NULL
mutant	NULL
of	NULL
the	NULL
CN	NULL
catalytic	NULL
subunit	NULL
(	NULL
pBJ5-CNAA	NULL
)	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
putative	NULL
auto-inhibitory	NULL
and	NULL
calmodulin-binding	NULL
domains	NULL
in	NULL
the	NULL
C-terminus	NULL
,	NULL
was	NULL
also	NULL
constructed	NULL
by	NULL
Dr.	NULL
Clipstone	NULL
.	NULL

Transfection	NULL
,	NULL
CAT	NULL
and	NULL
Luciferase	NULL
Assays	NULL
Transient	NULL
transfection	NULL
assay	NULL
was	NULL
done	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
)	NULL
,	NULL
except	NULL
for	NULL
the	NULL
experiments	NULL
of	NULL
lymphokine	NULL
production	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
washed	NULL
with	NULL
Tris-buffered	NULL
saline	NULL
were	NULL
suspended	NULL
in	NULL
3	NULL
ml	NULL
of	NULL
the	NULL
same	NULL
buffer	NULL
containing	NULL
DEAE-dextran	NULL
(	NULL
0.5	NULL
mg/ml	NULL
,	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
and	NULL
30-36	NULL
ug	NULL
of	NULL
total	NULL
plasmid	NULL
DNA	NULL
,	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
and	NULL
mixed	NULL
with	NULL
30	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
containing	NULL
0.1	NULL
mM	NULL
chloroquine	NULL
diphosphate	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
,	NULL
chloroquine-containing	NULL
medium	NULL
was	NULL
replaced	NULL
with	NULL
20	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
.	NULL

The	NULL
cell	NULL
suspension	NULL
was	NULL
divided	NULL
into	NULL
four	NULL
wells	NULL
of	NULL
a	NULL
6-well	NULL
plate	NULL
,	NULL
cultured	NULL
for	NULL
30	NULL
h	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
50	NULL
ng/ml	NULL
PMA	NULL
and	NULL
1	NULL
aM	NULL
A23187	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
0	NULL
,	NULL
0.01	NULL
or	NULL
1	NULL
ug/ml	NULL
CsA	NULL
for	NULL
12-15	NULL
h.	NULL
Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
four	NULL
cycles	NULL
of	NULL
freezing	NULL
and	NULL
thawing	NULL
,	NULL
and	NULL
subjected	NULL
to	NULL
CAT	NULL
and	NULL
luciferase	NULL
assays	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
AMBIS	NULL
image	NULL
analyzer	NULL
as	NULL
percentage	NULL
conversion	NULL
of	NULL
[	NULL
``	NULL
*C	NULL
)	NULL
chloramphenicol	NULL
to	NULL
1-	NULL
or	NULL
3-acetylated	NULL
chloramphenicol	NULL
after	NULL
6	NULL
h	NULL
incubation	NULL
at	NULL
37Â°C	NULL
with	NULL
50	NULL
ug	NULL
of	NULL
cell	NULL
extracts	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
luminometer	NULL
(	NULL
Monolight	NULL
2010	NULL
,	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
with	NULL
10	NULL
ul	NULL
of	NULL
50	NULL
ul	NULL
cell	NULL
extracts	NULL
,	NULL
followed	NULL
by	NULL
division	NULL
of	NULL
a	NULL
value	NULL
by	NULL
a	NULL
protein	NULL
amount	NULL
of	NULL
10	NULL
ul	NULL
extracts	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
de	NULL
Wet	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
(	NULL
Gene	NULL
Pulsar	NULL
,	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
to	NULL
measure	NULL
lymphokine	NULL
production	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
4	NULL
X	NULL
10	NULL
``	NULL
)	NULL
in	NULL
0.5	NULL
ml	NULL
RPMI	NULL
medium	NULL
were	NULL
mixed	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
DNA	NULL
in	NULL
0.4	NULL
cm	NULL
cuvettes	NULL
(	NULL
Bio-Rad	NULL
)	NULL
,	NULL
pulsed	NULL
at	NULL
300	NULL
V	NULL
(	NULL
960	NULL
LF	NULL
)	NULL
,	NULL
then	NULL
left	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
10	NULL
min	NULL
before	NULL
addition	NULL
of	NULL
10	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
after	NULL
which	NULL
the	NULL
mixture	NULL
was	NULL
transferred	NULL
to	NULL
plates	NULL
.	NULL

After	NULL
36	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
suspended	NULL
in	NULL
4	NULL
ml	NULL
of	NULL
culture	NULL
medium	NULL
,	NULL
divided	NULL
into	NULL
four	NULL
wells	NULL
of	NULL
16-well	NULL
plates	NULL
and	NULL
treated	NULL
with	NULL
various	NULL
reagents	NULL
for	NULL
24	NULL
h.	NULL
Vol	NULL
.	NULL

5	NULL
,	NULL
January	NULL
1994	NULL
Activation	NULL
of	NULL
GM-CSF	NULL
Gene	NULL
by	NULL
Calcineurin	NULL
RESULTS	NULL
CsA	NULL
Blocks	NULL
GM-CSF	NULL
Production	NULL
in	NULL
Jurkat	NULL
Cells	NULL
Jurkat	NULL
T	NULL
cells	NULL
produced	NULL
GM-CSF	NULL
when	NULL
co-stimulated	NULL
with	NULL
PMA	NULL
and	NULL
A23187	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

The	NULL
production	NULL
was	NULL
maximal	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
ng/	NULL
ml	NULL
PMA	NULL
and	NULL
1.0	NULL
4M	NULL
A23187	NULL
.	NULL

Either	NULL
PMA	NULL
or	NULL
A23187	NULL
did	NULL
not	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
GM-CSF	NULL
.	NULL

The	NULL
GM-CSF	NULL
production	NULL
,	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
,	NULL
was	NULL
inhibited	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
immunosuppressive	NULL
drug	NULL
CsA	NULL
,	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
A	NULL
3000	NULL
E	NULL
o	NULL
&	NULL
g	NULL
20004	NULL
9	NULL
0	NULL
3	NULL
``	NULL
J	NULL
0	NULL
L=	NULL
al	NULL
E	NULL
10004	NULL
w	NULL
Y	NULL
bs	NULL
O	NULL
0	NULL
O-	NULL
-O	NULL
O	NULL
0	NULL
10	NULL
20	NULL
50	NULL
PMA	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

B	NULL
3000	NULL
E	NULL
``	NULL
BD	NULL
&	NULL
S	NULL
2000	NULL
7	NULL
0	NULL
3	NULL
TV	NULL
0	NULL
=I	NULL
lant	NULL
a	NULL
1000	NULL
7	NULL
ja	NULL
ps	NULL
O	NULL
0	NULL
U	NULL
U	NULL
Ld	NULL
t	NULL
c	NULL
0	NULL
0.01	NULL
0.1	NULL
1.0	NULL
CsA	NULL
(	NULL
ug/ml	NULL
)	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
CsA	NULL
blocks	NULL
GM-CSF	NULL
production	NULL
induced	NULL
by	NULL
costimulation	NULL
with	NULL
PMA	NULL
and	NULL
A23187	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
0	NULL
,	NULL
10	NULL
,	NULL
20	NULL
,	NULL
and	NULL
50	NULL
ng/ml	NULL
of	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
A23187	NULL
:	NULL
0	NULL
gM	NULL
(	NULL
0	NULL
)	NULL
,	NULL
0.5	NULL
uM	NULL
(	NULL
@	NULL
)	NULL
,	NULL
1.0	NULL
aM	NULL
(	NULL
Â®	NULL
)	NULL
and	NULL
2.5	NULL
uM	NULL
(	NULL
&	NULL
)	NULL
.	NULL

GM-CSF	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
after	NULL
24	NULL
h	NULL
incubation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
A23187	NULL
(	NULL
1.0	NULL
uM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
0	NULL
,	NULL
0.01	NULL
,	NULL
0.1	NULL
,	NULL
or	NULL
1.0	NULL
ug/ml	NULL
)	NULL
.	NULL

Results	NULL
shown	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
3	NULL
experiments	NULL
.	NULL

121	NULL
A.	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

IL-2	NULL
production	NULL
was	NULL
induced	NULL
by	NULL
co-stimulation	NULL
with	NULL
PMA/A23187	NULL
and	NULL
was	NULL
blocked	NULL
by	NULL
CsA	NULL
treatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
show	NULL
strong	NULL
synergy	NULL
between	NULL
PKC-	NULL
and	NULL
Ca**-signaling	NULL
pathways	NULL
for	NULL
the	NULL
production	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
,	NULL
which	NULL
is	NULL
completely	NULL
inhibited	NULL
by	NULL
addition	NULL
of	NULL
CsA	NULL
.	NULL

CLEO	NULL
Motif	NULL
Is	NULL
Recognized	NULL
by	NULL
a	NULL
CsA-sensitive	NULL
NF	NULL
AT	NULL
-like	NULL
Factor	NULL
Mobility	NULL
shift	NULL
assays	NULL
using	NULL
nuclear	NULL
extracts	NULL
of	NULL
Jurkat	NULL
cells	NULL
were	NULL
performed	NULL
to	NULL
identify	NULL
PMA/A23187-induced	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
,	NULL
whose	NULL
binding	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
,	NULL
in	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

A1	NULL
,	NULL
A2	NULL
,	NULL
and	NULL
B	NULL
bindings	NULL
to	NULL
the	NULL
GC-box	NULL
sequence	NULL
(	NULL
gm-mu	NULL
7.8	NULL
)	NULL
were	NULL
constitutive	NULL
and	NULL
were	NULL
not	NULL
affected	NULL
significantly	NULL
by	NULL
any	NULL
treatment	NULL
given	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

NF-	NULL
Â«	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
sequence	NULL
(	NULL
gm-mu	NULL
17.18	NULL
)	NULL
was	NULL
significantly	NULL
induced	NULL
by	NULL
PMA	NULL
alone	NULL
.	NULL

PMA/A23187	NULL
treatment	NULL
slightly	NULL
increased	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
activity	NULL
(	NULL
<	NULL
1.5-fold	NULL
)	NULL
,	NULL
and	NULL
CsA	NULL
treatment	NULL
inhibited	NULL
the	NULL
PMA/A23187-induced	NULL
binding	NULL
,	NULL
to	NULL
the	NULL
PMA-induced	NULL
level	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

We	NULL
found	NULL
in	NULL
earlier	NULL
mobility	NULL
shift	NULL
assays	NULL
that	NULL
the	NULL
CLEO	NULL
sequence	NULL
gives	NULL
rise	NULL
to	NULL
at	NULL
least	NULL
three	NULL
DNA-protein	NULL
com-plexes	NULL
,	NULL
termed	NULL
NF-CLEO	NULL
a	NULL
,	NULL
8	NULL
,	NULL
and	NULL
y	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

A	NULL
basal	NULL
level	NULL
of	NULL
NF-CLEO	NULL
a	NULL
and	NULL
8	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
non-stimulated	NULL
nuclear	NULL
extracts	NULL
and	NULL
were	NULL
induced	NULL
markedly	NULL
by	NULL
PMA	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

PMA/A23187	NULL
treatment	NULL
further	NULL
increased	NULL
the	NULL
a-	NULL
and	NULL
-binding	NULL
activities	NULL
less	NULL
than	NULL
threefold	NULL
,	NULL
and	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
was	NULL
without	NULL
effect	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
evidence	NULL
including	NULL
the	NULL
binding	NULL
of	NULL
partially	NULL
purified	NULL
AP-1	NULL
to	NULL
CLEO	NULL
sequence	NULL
,	NULL
GC-box	NULL
GM-xB	NULL
B	NULL
,	NULL
Probe	NULL
(	NULL
gm-mu	NULL
7	NULL
.	NULL

8	NULL
)	NULL
(	NULL
gm-mu	NULL
17	NULL
.	NULL

18	NULL
)	NULL
Probe	NULL
f	NULL
PMA	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
PMA	NULL
A23187	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
A23187	NULL
CsA	NULL
+	NULL
+	NULL
CsA	NULL
%	NULL
.	NULL

-	NULL
)	NULL
tod	NULL
tad	NULL
bat	NULL
tost	NULL
tos	NULL
bnt	NULL
Wi	NULL
<	NULL
nros	NULL
5	NULL
-	NULL
Â»	NULL
Wis	NULL
tno	NULL
wa	NULL
Bane	NULL
||	NULL
B	NULL
Lg	NULL
:	NULL
â	NULL
aw-Mink	NULL
hike	NULL
<	NULL
)	NULL
>	NULL
indicated	NULL
that	NULL
these	NULL
are	NULL
related	NULL
to	NULL
AP-1	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NF-CLEO	NULL
y	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
PMA	NULL
or	NULL
A23187	NULL
alone	NULL
,	NULL
but	NULL
was	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

This	NULL
binding	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
adding	NULL
CsA	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
NF-AT-binding	NULL
sequence	NULL
competitively	NULL
inhibited	NULL
NF-CLEO	NULL
7	NULL
binding	NULL
,	NULL
but	NULL
not	NULL
a	NULL
and	NULL
8	NULL
bindings	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
is	NULL
one	NULL
of	NULL
the	NULL
targets	NULL
for	NULL
the	NULL
NF-AT-related	NULL
factor	NULL
,	NULL
which	NULL
is	NULL
induced	NULL
by	NULL
co-stimulation	NULL
with	NULL
PMA/A23187	NULL
and	NULL
blocked	NULL
by	NULL
CsA	NULL
treatment	NULL
.	NULL

Overexpression	NULL
of	NULL
CN	NULL
Potentiates	NULL
Transcriptional	NULL
Activation	NULL
from	NULL
the	NULL
GM-CSF	NULL
Promoter	NULL
in	NULL
Jurkat	NULL
Cells	NULL
Since	NULL
CN	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
implicated	NULL
in	NULL
the	NULL
Ca**-signaling	NULL
pathway	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
induction	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
CN	NULL
on	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
carry	NULL
cDNAs	NULL
for	NULL
the	NULL
catalytic	NULL
(	NULL
A	NULL
)	NULL
and	NULL
regulatory	NULL
(	NULL
B	NULL
)	NULL
subunits	NULL
of	NULL
CN	NULL
,	NULL
respectively	NULL
(	NULL
Clipstone	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

pKC1	NULL
is	NULL
a	NULL
CAT	NULL
reporter	NULL
construct	NULL
carrying	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
between	NULL
positions	NULL
-97	NULL
and	NULL
+27	NULL
.	NULL

First	NULL
we	NULL
co-transfected	NULL
pKC1	NULL
with	NULL
a	NULL
control	NULL
vector	NULL
pBJ5	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

PMA	NULL
alone	NULL
slightly	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
while	NULL
A23187	NULL
alone	NULL
did	NULL
not	NULL
.	NULL

PMA/	NULL
A23187	NULL
treatment	NULL
synergistically	NULL
induced	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
was	NULL
inhibited	NULL
by	NULL
CsA	NULL
,	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

Co-transfection	NULL
of	NULL
pKC1	NULL
with	NULL
pBJ5-CNA	NULL
and	NULL
pBJ5	NULL
C	NULL
CLEO	NULL
Competitor	NULL
--	NULL
CLEO	NULL
NF-AT	NULL
Spl	NULL
Y	NULL
-	NULL
Â»	NULL
j	NULL
o	NULL
-	NULL
#	NULL
Â»	NULL
h	NULL
p	NULL
+++	NULL
Figure	NULL
2	NULL
.	NULL

-	NULL
CLEO	NULL
element	NULL
is	NULL
recognized	NULL
by	NULL
an	NULL
NF-AT-like	NULL
factor	NULL
whose	NULL
binding	NULL
is	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
and	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
either	NULL
non-A23187-	NULL
,	NULL
PMA-	NULL
,	NULL
PMA/A23187-	NULL
,	NULL
or	NULL
PMA/A23187/CsA-stimulated	NULL
Jurkat	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
GC-box	NULL
(	NULL
A	NULL
)	NULL
,	NULL
GM-	NULL
Â«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
or	NULL
CLEO	NULL
(	NULL
B	NULL
)	NULL
oligonucleotides	NULL
labeled	NULL
with	NULL
**P	NULL
,	NULL
followed	NULL
by	NULL
native	NULL
acrylamide	NULL
gel	NULL
electrophoresis	NULL
and	NULL
autoradiography	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Nuclear	NULL
extracts	NULL
of	NULL
PMA/A23187-stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
**P-labeled	NULL
CLEO	NULL
oligonucleotides	NULL
together	NULL
with	NULL
a	NULL
competitor	NULL
of	NULL
either	NULL
CLEO	NULL
,	NULL
NF-AT	NULL
or	NULL
Sp1	NULL
oligonucleotides	NULL
at	NULL
the	NULL
concentration	NULL
of	NULL
0.5	NULL
,	NULL
5	NULL
,	NULL
and	NULL
50	NULL
ng	NULL
.	NULL

The	NULL
following	NULL
amounts	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
used	NULL
for	NULL
assays	NULL
:	NULL
GC-box	NULL
(	NULL
A	NULL
)	NULL
,	NULL
2.5	NULL
ug	NULL
,	NULL
GM-	NULL
Â«	NULL
B	NULL
(	NULL
A	NULL
)	NULL
,	NULL
10	NULL
ug	NULL
,	NULL
(	NULL
B	NULL
)	NULL
,	NULL
12	NULL
ug	NULL
,	NULL
and	NULL
(	NULL
C	NULL
)	NULL
,	NULL
12	NULL
ug	NULL
.	NULL

122	NULL
Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL
A	NULL
Reporter	NULL
pKC1	NULL
(	NULL
GM-CSF	NULL
promoter	NULL
)	NULL
CN	NULL
A	NULL
&	NULL
B	NULL
ook	NULL
(	NULL
m	NULL
oe	NULL
poop	NULL
$	NULL
oo	NULL
#	NULL
PMA/A23187	NULL
_	NULL
=	NULL
+	NULL
+	NULL
+	NULL
=	NULL
+	NULL
+	NULL
+	NULL
CsA	NULL
(	NULL
ug/ml	NULL
)	NULL
0	NULL
_	NULL
0	NULL
0.01	NULL
10	NULL
0	NULL
0	NULL
0.01	NULL
1	NULL
#	NULL
|	NULL
Â©	NULL
#	NULL
e	NULL
Y	NULL
o	NULL
_o	NULL
Y	NULL
6	NULL
+	NULL
%	NULL
Relative	NULL
activity	NULL
1	NULL
9.7	NULL
3.0	NULL
13	NULL
1	NULL
28	NULL
13	NULL
12	NULL
Relative	NULL
CAT	NULL
activity	NULL
(	NULL
fold	NULL
induction	NULL
)	NULL
CN	NULL
A	NULL
&	NULL
B	NULL
sos	NULL
soz	NULL
PMA/A23187	NULL
CsA	NULL
(	NULL
ug/ml	NULL
)	NULL
~	NULL
og	NULL
t	NULL
+	NULL
0	NULL
0	NULL
0.01	NULL
1	NULL
Figure	NULL
3	NULL
.	NULL

-	NULL
Exogenously	NULL
expressed	NULL
CN	NULL
in	NULL
Jurkat	NULL
cells	NULL
stimulates	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
promoters	NULL
and	NULL
restores	NULL
the	NULL
transcription	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
co-transfected	NULL
either	NULL
with	NULL
12	NULL
ug	NULL
of	NULL
pKC1	NULL
(	NULL
A	NULL
)	NULL
or	NULL
pIL-2	NULL
CAT-1	NULL
(	NULL
B	NULL
)	NULL
together	NULL
with	NULL
either	NULL
pBJ5	NULL
(	NULL
24	NULL
ug	NULL
)	NULL
or	NULL
pBJ5-CNA	NULL
(	NULL
12	NULL
ug	NULL
)	NULL
and	NULL
pBJ5-CNB	NULL
(	NULL
12	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
divided	NULL
into	NULL
4	NULL
aliquots	NULL
.	NULL

After	NULL
30	NULL
h	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
15	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
!	NULL
)	NULL

and	NULL
A23187	NULL
(	NULL
1	NULL
aM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
0	NULL
,	NULL
0.01	NULL
,	NULL
or	NULL
1.0	NULL
ug/ml	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
as	NULL
thin	NULL
layer	NULL
chromatogram	NULL
(	NULL
A	NULL
)	NULL
,	NULL
quantitated	NULL
as	NULL
fold	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
and	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Means	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
SD	NULL
)	NULL
are	NULL
1	NULL
+	NULL
0.34	NULL
,	NULL
9.7	NULL
+	NULL
1.6	NULL
,	NULL
3.0	NULL
+	NULL
1.2	NULL
,	NULL
1.3	NULL
+	NULL
0.14	NULL
,	NULL
1	NULL
+	NULL
0.065	NULL
,	NULL
28	NULL
+	NULL
5.7	NULL
,	NULL
13	NULL
+	NULL
2.3	NULL
,	NULL
and	NULL
1.2	NULL
+	NULL
0.26	NULL
(	NULL
A	NULL
)	NULL
;	NULL
and	NULL
1	NULL
+	NULL
0.50	NULL
,	NULL
69	NULL
+	NULL
11	NULL
,	NULL
3.5	NULL
+	NULL
4.4	NULL
,	NULL
0.94	NULL
+	NULL
0.20	NULL
,	NULL
1	NULL
+	NULL
0.24	NULL
,	NULL
220	NULL
+	NULL
30	NULL
,	NULL
110	NULL
+	NULL
18	NULL
,	NULL
and	NULL
1.2	NULL
+	NULL
0.32	NULL
(	NULL
B	NULL
)	NULL
.	NULL

CNB	NULL
enhanced	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
threefold	NULL
and	NULL
recovered	NULL
the	NULL
transcription	NULL
inhibited	NULL
by	NULL
0.01	NULL
ug/ml	NULL
of	NULL
CsA	NULL
,	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
we	NULL
co-transfected	NULL
pIL-2	NULL
CAT-1	NULL
(	NULL
-567	NULL
to	NULL
+47	NULL
)	NULL
along	NULL
with	NULL
pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Overexpression	NULL
of	NULL
CN	NULL
augmented	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
more	NULL
than	NULL
threefold	NULL
and	NULL
restored	NULL
the	NULL
transcription	NULL
reduced	NULL
by	NULL
CsA	NULL
in	NULL
the	NULL
concentration	NULL
of	NULL
0.01	NULL
ug/ml	NULL
,	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
overexpressed	NULL
CN	NULL
potentiates	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
in	NULL
response	NULL
to	NULL
PMA/A23187	NULL
and	NULL
confers	NULL
CsA	NULL
resistance	NULL
on	NULL
the	NULL
transcription	NULL
.	NULL

Expression	NULL
of	NULL
Constitutively	NULL
Active	NULL
CN	NULL
Acts	NULL
in	NULL
Synergy	NULL
with	NULL
PMA	NULL
to	NULL
Facilitate	NULL
Transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
Promoter	NULL
To	NULL
further	NULL
examine	NULL
the	NULL
CN	NULL
action	NULL
on	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
co-transfection	NULL
experiments	NULL
using	NULL
Vol	NULL
.	NULL

5	NULL
,	NULL
January	NULL
1994	NULL
Activation	NULL
of	NULL
GM-CSF	NULL
Gene	NULL
by	NULL
Calcineurin	NULL
a	NULL
deletion	NULL
mutant	NULL
of	NULL
the	NULL
CN	NULL
catalytic	NULL
subunit	NULL
(	NULL
pBJ5-CNAA	NULL
)	NULL
.	NULL

This	NULL
mutation	NULL
,	NULL
which	NULL
lacks	NULL
the	NULL
putative	NULL
autoinhibitory	NULL
and	NULL
calmodulin-binding	NULL
domains	NULL
,	NULL
gives	NULL
rise	NULL
to	NULL
Ca**/calmodulin-independent	NULL
,	NULL
constitutive	NULL
phosphatase	NULL
activity	NULL
(	NULL
Clipstone	NULL
,	NULL
personal	NULL
communication	NULL
)	NULL
.	NULL

pKC17	NULL
is	NULL
a	NULL
luciferase	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
between	NULL
-97	NULL
and	NULL
+27	NULL
.	NULL

First	NULL
we	NULL
co-transfected	NULL
pKC17	NULL
with	NULL
the	NULL
control	NULL
vector	NULL
pBJ5	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

PMA	NULL
alone	NULL
slightly	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
activation	NULL
was	NULL
not	NULL
blocked	NULL
by	NULL
addition	NULL
of	NULL
CsA	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

Co-trans-	NULL
A	NULL
200	NULL
GM-CSF	NULL
aa	NULL
o	NULL
T	NULL
Relative	NULL
luciferase	NULL
activity	NULL
(	NULL
fold	NULL
induction	NULL
)	NULL
0-CN	NULL
AA	NULL
PMA	NULL
CsA	NULL
(	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
B	NULL
607	NULL
so-40-	NULL
207	NULL
Relative	NULL
luciferase	NULL
activity	NULL
(	NULL
fold	NULL
induction	NULL
)	NULL
104	NULL
0	NULL
CN	NULL
AA	NULL
-o-	NULL
-	NULL
-	NULL
+	NULL
+o	NULL
+	NULL
+	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
+	NULL
CsA	NULL
(	NULL
ug/ml	NULL
)	NULL
_	NULL
0	NULL
0	NULL
0.01	NULL
1	NULL
0	NULL
o	NULL
0.01	NULL
1	NULL
Figure	NULL
4	NULL
.	NULL

Expression	NULL
of	NULL
constitutively	NULL
active	NULL
CN	NULL
synergizes	NULL
with	NULL
PMA	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
promoters	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
2	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
co-transfected	NULL
either	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
pKC17	NULL
(	NULL
A	NULL
)	NULL
or	NULL
pIL-2	NULL
Luc-1	NULL
(	NULL
B	NULL
)	NULL
along	NULL
with	NULL
either	NULL
pBJ5	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
or	NULL
pBJ5-CNAA	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
and	NULL
divided	NULL
into	NULL
4	NULL
aliquots	NULL
.	NULL

After	NULL
30	NULL
h	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
12	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
0	NULL
,	NULL
0.01	NULL
,	NULL
or	NULL
1.0	NULL
ug/ml	NULL
)	NULL
.	NULL

Results	NULL
presented	NULL
are	NULL
quantitated	NULL
as	NULL
fold	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
and	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Means	NULL
and	NULL
SD	NULL
are	NULL
1	NULL
+	NULL
0.24	NULL
,	NULL
28	NULL
+	NULL
9.5	NULL
,	NULL
30	NULL
+	NULL
7.0	NULL
,	NULL
21	NULL
+	NULL
7.2	NULL
,	NULL
1	NULL
+	NULL
0.44	NULL
,	NULL
130	NULL
+	NULL
32	NULL
,	NULL
64	NULL
+	NULL
16	NULL
and	NULL
12	NULL
+	NULL
4.2	NULL
(	NULL
A	NULL
)	NULL
,	NULL
and	NULL
1	NULL
+	NULL
0.28	NULL
,	NULL
1.3	NULL
+	NULL
0.070	NULL
,	NULL
1.2	NULL
+	NULL
0.36	NULL
,	NULL
1.2	NULL
+	NULL
0.15	NULL
,	NULL
1	NULL
+	NULL
0.42	NULL
,	NULL
53	NULL
+	NULL
23	NULL
,	NULL
15	NULL
+	NULL
6.2	NULL
and	NULL
1.6	NULL
+	NULL
0.17	NULL
(	NULL
B	NULL
)	NULL
.	NULL

123	NULL
A.	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

fection	NULL
of	NULL
pKC17	NULL
with	NULL
pBJ5-CNAA	NULL
enhanced	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
4.5-fold	NULL
and	NULL
rendered	NULL
the	NULL
cells	NULL
more	NULL
resistant	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
(	NULL
0.01	NULL
ug/ml	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

As	NULL
a	NULL
control	NULL
experiment	NULL
,	NULL
we	NULL
co-transfected	NULL
pIL-2	NULL
Luc-1	NULL
(	NULL
-567	NULL
to	NULL
+47	NULL
)	NULL
along	NULL
with	NULL
pBJ5-CNAA	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
activated	NULL
CN	NULL
stimulated	NULL
transcription	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
40-fold	NULL
and	NULL
also	NULL
made	NULL
the	NULL
cells	NULL
more	NULL
resistant	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
(	NULL
0.01	NULL
ug/ml	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
4B	NULL
)	NULL
.	NULL

It	NULL
would	NULL
thus	NULL
appear	NULL
that	NULL
the	NULL
region	NULL
between	NULL
-97	NULL
and	NULL
+27	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
the	NULL
activated	NULL
CN	NULL
with	NULL
PMA	NULL
.	NULL

Constitutively	NULL
Active	NULL
CN	NULL
Acts	NULL
in	NULL
Synergy	NULL
with	NULL
PMA	NULL
to	NULL
Induce	NULL
Production	NULL
of	NULL
Endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
To	NULL
determine	NULL
whether	NULL
increases	NULL
in	NULL
luciferase	NULL
activity	NULL
by	NULL
the	NULL
synergistic	NULL
action	NULL
of	NULL
the	NULL
constitutively	NULL
active	NULL
CN	NULL
with	NULL
PMA	NULL
were	NULL
indeed	NULL
a	NULL
consequence	NULL
of	NULL
enhancement	NULL
of	NULL
signals	NULL
converging	NULL
on	NULL
the	NULL
GM-CSF	NULL
or	NULL
IL-2	NULL
gene	NULL
,	NULL
we	NULL
measured	NULL
the	NULL
amount	NULL
of	NULL
endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
proteins	NULL
,	NULL
Culture	NULL
supernatants	NULL
from	NULL
Jurkat	NULL
cells	NULL
,	NULL
transfected	NULL
transiently	NULL
with	NULL
the	NULL
active	NULL
CN	NULL
,	NULL
were	NULL
assayed	NULL
for	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
levels	NULL
,	NULL
following	NULL
treatment	NULL
of	NULL
various	NULL
reagents	NULL
.	NULL

Transfected	NULL
cells	NULL
with	NULL
the	NULL
control	NULL
vector	NULL
pBJ5	NULL
produced	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
only	NULL
when	NULL
stimulated	NULL
with	NULL
PMA/A23187	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
transfection	NULL
with	NULL
pBJ5-CNAA	NULL
revealed	NULL
that	NULL
expression	NULL
of	NULL
the	NULL
constitutively	NULL
active	NULL
CN	NULL
synergized	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
production	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
,	NULL
both	NULL
of	NULL
which	NULL
were	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
production	NULL
were	NULL
,	NULL
however	NULL
,	NULL
lower	NULL
compared	NULL
with	NULL
those	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
in	NULL
the	NULL
pBJ5-transfected	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
behavior	NULL
of	NULL
the	NULL
plasmids	NULL
pKC17	NULL
and	NULL
pIL-2	NULL
Luc-1	NULL
reflects	NULL
the	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
genes	NULL
,	NULL
respectively	NULL
.	NULL

Exogenously	NULL
Expressed	NULL
CN	NULL
Augments	NULL
CLEO-Dependent	NULL
Transcription	NULL
To	NULL
characterize	NULL
CN	NULL
responsive	NULL
element	NULL
(	NULL
s	NULL
)	NULL
in	NULL
detail	NULL
,	NULL
we	NULL
divided	NULL
the	NULL
region	NULL
between	NULL
-91	NULL
and	NULL
-37	NULL
into	NULL
two	NULL
seg-ments	NULL
,	NULL
followed	NULL
by	NULL
insertion	NULL
into	NULL
the	NULL
minimal	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
position	NULL
-36	NULL
to	NULL
+27	NULL
)	NULL
.	NULL

p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
CAT	NULL
and	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
contain	NULL
two	NULL
copies	NULL
of	NULL
segment	NULL
-91	NULL
to	NULL
-72	NULL
and	NULL
segment	NULL
-70	NULL
to	NULL
-37	NULL
,	NULL
respectively	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

PMA/A23187	NULL
treatment	NULL
induced	NULL
transcription	NULL
from	NULL
p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
,	NULL
CAT	NULL
in	NULL
a	NULL
lower	NULL
level	NULL
than	NULL
that	NULL
from	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
CAT	NULL
.	NULL

Co-transfection	NULL
of	NULL
p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/	NULL
GC-box	NULL
)	NULL
,	NULL
CAT	NULL
with	NULL
pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
stimulated	NULL
transcription	NULL
1.5-fold	NULL
compared	NULL
with	NULL
pBJ5	NULL
,	NULL
whereas	NULL
co-transfection	NULL
of	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
CAT	NULL
with	NULL
pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
enhanced	NULL
transcription	NULL
twofold	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
stimulation	NULL
by	NULL
CN	NULL
in	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
,	NULL
CAT	NULL
was	NULL
more	NULL
than	NULL
threefold	NULL
124	NULL
A	NULL
4007	NULL
g/ml	NULL
)	NULL
2300-	NULL
2004	NULL
M-CSF	NULL
production	NULL
a	NULL
t	NULL
4+	NULL
$	NULL
9	NULL
+o	NULL
++	NULL
1	NULL
++	NULL
+	NULL
2000	NULL
7	NULL
10007	NULL
IL-2	NULL
production	NULL
(	NULL
pg/ml	NULL
)	NULL
0	NULL
CNAA	NULL
=	NULL
o=	NULL
PMA	NULL
=	NULL
+	NULL
A23187	NULL
=	NULL
=	NULL
CsA	NULL
e	NULL
a	NULL
4	NULL
$	NULL
or	NULL
+	NULL
4	NULL
$	NULL
01	NULL
Figure	NULL
5	NULL
.	NULL

Constitutively	NULL
active	NULL
CN	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
production	NULL
of	NULL
endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Cells	NULL
(	NULL
4	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
either	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
pBJ5	NULL
or	NULL
pBJ5-CNAA	NULL
.	NULL

After	NULL
36	NULL
h	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
harvested	NULL
,	NULL
suspended	NULL
in	NULL
culture	NULL
medium	NULL
,	NULL
divided	NULL
into	NULL
4	NULL
wells	NULL
of	NULL
16-well	NULL
plates	NULL
and	NULL
stimulated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and/or	NULL
A23187	NULL
(	NULL
1	NULL
LM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
0	NULL
or	NULL
1.0	NULL
ug/ml	NULL
)	NULL
.	NULL

Results	NULL
presented	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Detection	NULL
limits	NULL
in	NULL
ELISA	NULL
were	NULL
40	NULL
pg/ml	NULL
for	NULL
GM-CSF	NULL
and	NULL
200	NULL
pg/ml	NULL
for	NULL
IL-2	NULL
.	NULL

higher	NULL
than	NULL
that	NULL
in	NULL
p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
,	NULL
CAT	NULL
.	NULL

It	NULL
may	NULL
well	NULL
be	NULL
that	NULL
the	NULL
CLEO	NULL
element	NULL
more	NULL
than	NULL
the	NULL
GM-	NULL
Â«	NULL
B/	NULL
GC-box	NULL
sequence	NULL
is	NULL
responsible	NULL
for	NULL
both	NULL
the	NULL
inducibility	NULL
by	NULL
PMA/A23187	NULL
and	NULL
the	NULL
potentiation	NULL
by	NULL
CN	NULL
.	NULL

We	NULL
then	NULL
constructed	NULL
a	NULL
plasmid	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
CLEO	NULL
element	NULL
(	NULL
position	NULL
-57	NULL
to	NULL
-37	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
basal	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Figure	NULL
6D	NULL
)	NULL
.	NULL

Co-transfection	NULL
of	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
;	NULL
CAT	NULL
with	NULL
pBJ5-CNA	NULL
and	NULL
pBJ5-CNB	NULL
showed	NULL
that	NULL
expression	NULL
of	NULL
CN	NULL
augmented	NULL
the	NULL
CLEO-dependent	NULL
transcription	NULL
threefold	NULL
compared	NULL
with	NULL
pBJ5	NULL
(	NULL
Figure	NULL
6C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
like	NULL
the	NULL
NF-AT	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
the	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL
gene	NULL
is	NULL
one	NULL
target	NULL
for	NULL
enhancement	NULL
of	NULL
transcription	NULL
by	NULL
CN	NULL
and	NULL
for	NULL
induction	NULL
through	NULL
the	NULL
PKC-	NULL
and	NULL
Ca**-signaling	NULL
pathways	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

DISCUSSION	NULL
In	NULL
T	NULL
cells	NULL
,	NULL
co-stimulation	NULL
with	NULL
phorbol	NULL
esters	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
Ca*	NULL
``	NULL
*	NULL
ionophores	NULL
(	NULL
A23187	NULL
)	NULL
leads	NULL
to	NULL
considerable	NULL
activation	NULL
of	NULL
several	NULL
lymphokine	NULL
genes	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
production	NULL
of	NULL
IL-2	NULL
or	NULL
GM-CSF	NULL
shows	NULL
strong	NULL
synergy	NULL
between	NULL
PKC-	NULL
and	NULL
Ca**-signaling	NULL
pathways	NULL
both	NULL
in	NULL
murine	NULL
cloned	NULL
T	NULL
cells	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
and	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

In	NULL
cloned	NULL
T	NULL
cells	NULL
,	NULL
certain	NULL
lymphokines	NULL
are	NULL
partially	NULL
activated	NULL
by	NULL
PMA	NULL
alone	NULL
(	NULL
IL-5	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-10	NULL
)	NULL
or	NULL
A23187	NULL
alone	NULL
(	NULL
IL-3	NULL
,	NULL
IL-4	NULL
and	NULL
interferon	NULL
[	NULL
IFN	NULL
]	NULL
-y	NULL
)	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

CsA	NULL
completely	NULL
inhibits	NULL
the	NULL
IL-2	NULL
and	NULL
GM-CSF	NULL
production	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
in	NULL
both	NULL
these	NULL
T	NULL
cell	NULL
lines	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

In	NULL
the	NULL
cloned	NULL
T	NULL
cells	NULL
,	NULL
CsA	NULL
almost	NULL
completely	NULL
blocks	NULL
the	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IFN-y	NULL
production	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
in	NULL
activated	NULL
human	NULL
lymphocytes	NULL
,	NULL
CsA	NULL
and	NULL
FK506	NULL
inhibit	NULL
accumulation	NULL
of	NULL
transcripts	NULL
from	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IFN-y	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
Tocci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
on	NULL
the	NULL
IL-2	NULL
gene	NULL
showed	NULL
that	NULL
both	NULL
transcriptional	NULL
activation	NULL
through	NULL
two	NULL
NF-AT	NULL
sites	NULL
and	NULL
an	NULL
Oct-1	NULL
(	NULL
octamer	NULL
factor-1	NULL
)	NULL
/OAP-40	NULL
(	NULL
octamer-asso-ciated	NULL
protein-40	NULL
)	NULL
site	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
and	NULL
the	NULL
respective	NULL
DNA	NULL
bindings	NULL
are	NULL
highly	NULL
sensitive	NULL
to	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
Riegel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

NF-AT	NULL
consists	NULL
of	NULL
two	NULL
factors	NULL
:	NULL
a	NULL
ubiquitous	NULL
nuclear	NULL
factor	NULL
(	NULL
NF-AT	NULL
,	NULL
)	NULL
,	NULL
identified	NULL
as	NULL
AP-1	NULL
consisting	NULL
of	NULL
Jun-Fos	NULL
heterodimers	NULL
such	NULL
as	NULL
Fral	NULL
/JunB	NULL
(	NULL
Jain	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Boise	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
and	NULL
a	NULL
T	NULL
cell-specific	NULL
,	NULL
pre-existing	NULL
component	NULL
(	NULL
NF-AT	NULL
,	NULL
)	NULL
,	NULL
whose	NULL
translocation	NULL
from	NULL
cytoplasm	NULL
into	NULL
nucleus	NULL
is	NULL
inhibited	NULL
by	NULL
CsA	NULL
and	NULL
FK506	NULL
(	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
foregoing	NULL
work	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
the	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
is	NULL
recognized	NULL
by	NULL
NF-CLEO	NULL
y	NULL
with	NULL
a	NULL
relatively	NULL
weak	NULL
affinity	NULL
.	NULL

NF-CLEO	NULL
7	NULL
is	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
,	NULL
abolished	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
and	NULL
competitively	NULL
inhibited	NULL
by	NULL
NF-AT	NULL
oligonucleotides	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

NF-CLEO	NULL
y	NULL
has	NULL
other	NULL
characteristics	NULL
similar	NULL
to	NULL
NF-AT	NULL
,	NULL
since	NULL
it	NULL
appears	NULL
to	NULL
be	NULL
composed	NULL
of	NULL
AP-1	NULL
and	NULL
120	NULL
kDa	NULL
protein	NULL
(	NULL
Tokumitsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
CLEO	NULL
element	NULL
shares	NULL
partial	NULL
homology	NULL
with	NULL
the	NULL
-binding	NULL
site	NULL
(	NULL
TTTCCTC	NULL
,	NULL
Figure	NULL
7	NULL
)	NULL
,	NULL
which	NULL
is	NULL
closely	NULL
related	NULL
to	NULL
the	NULL
consensus	NULL
binding	NULL
sequence	NULL
for	NULL
Ets-family	NULL
proteins	NULL
(	NULL
Wasylyk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
CLEO	NULL
sequence	NULL
contains	NULL
an	NULL
AP-1	NULL
-like	NULL
site	NULL
juxtaposed	NULL
directly	NULL
with	NULL
the	NULL
Ets-binding	NULL
site	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

The	NULL
CLEO-AP-1	NULL
site	NULL
(	NULL
TTAATCA	NULL
)	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
sequence	NULL
(	NULL
TGAG/CTCA	NULL
)	NULL
,	NULL
and	NULL
differences	NULL
are	NULL
probably	NULL
not	NULL
critical	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
Jun-Fos	NULL
heterodimer	NULL
(	NULL
Risse	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
since	NULL
AP-1	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
CLEO	NULL
sequence	NULL
with	NULL
a	NULL
high	NULL
affinity	NULL
(	NULL
Tokumitsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

NF-CLEO	NULL
a	NULL
and	NULL
$	NULL
are	NULL
induced	NULL
Vol	NULL
.	NULL

5	NULL
,	NULL
January	NULL
1994	NULL
Activation	NULL
of	NULL
GM-CSF	NULL
Gene	NULL
by	NULL
Calcineurin	NULL
mainly	NULL
by	NULL
PMA	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
and	NULL
share	NULL
most	NULL
properties	NULL
with	NULL
AP-1	NULL
(	NULL
Masuda	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

CsA	NULL
and	NULL
FK506	NULL
tightly	NULL
bind	NULL
distinct	NULL
families	NULL
of	NULL
im-munophilin	NULL
(	NULL
Schreiber	NULL
and	NULL
Crabtree	NULL
,	NULL
1992	NULL
;	NULL
Sigal	NULL
and	NULL
Dumont	NULL
,	NULL
1992	NULL
)	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
complexes	NULL
associate	NULL
with	NULL
CN	NULL
to	NULL
inhibit	NULL
phosphatase	NULL
activity	NULL
(	NULL
Fruman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
CN	NULL
is	NULL
expressed	NULL
at	NULL
a	NULL
low	NULL
level	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
Kincaid	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
,	NULL
1990	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
immunophilins	NULL
are	NULL
relatively	NULL
abundant	NULL
(	NULL
Sigal	NULL
and	NULL
Dumont	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

We	NULL
showed	NULL
that	NULL
as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
,	NULL
overexpression	NULL
of	NULL
CNA/CNB	NULL
augments	NULL
transcription	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
and	NULL
restores	NULL
the	NULL
transcription	NULL
inhibited	NULL
by	NULL
CsA	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
.	NULL

We	NULL
also	NULL
found	NULL
that	NULL
the	NULL
constitutively	NULL
active	NULL
form	NULL
of	NULL
CNA	NULL
subunit	NULL
synergizes	NULL
with	NULL
PMA	NULL
to	NULL
stimulate	NULL
transcription	NULL
from	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
,	NULL
as	NULL
described	NULL
in	NULL
the	NULL
earlier	NULL
study	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
O'Keefe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Finally	NULL
we	NULL
demonstrated	NULL
that	NULL
the	NULL
constitutively	NULL
active	NULL
CN	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
induce	NULL
production	NULL
of	NULL
endogenous	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
(	NULL
Figure	NULL
5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
induction	NULL
by	NULL
PMA	NULL
are	NULL
lower	NULL
than	NULL
those	NULL
induced	NULL
by	NULL
PMA	NULL
/	NULL
A23187	NULL
in	NULL
mock-transfected	NULL
cells	NULL
,	NULL
as	NULL
probably	NULL
related	NULL
to	NULL
transfection	NULL
efficiency	NULL
.	NULL

This	NULL
would	NULL
not	NULL
,	NULL
however	NULL
,	NULL
account	NULL
for	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
lymphokine	NULL
production	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
in	NULL
CNAA-transfected	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
CLEO	NULL
sequence-dependent	NULL
transcription	NULL
is	NULL
stimulated	NULL
by	NULL
the	NULL
expression	NULL
of	NULL
CNA/CNB	NULL
(	NULL
Figure	NULL
6C	NULL
)	NULL
as	NULL
well	NULL
as	NULL
by	NULL
that	NULL
of	NULL
the	NULL
constitutively	NULL
active	NULL
type	NULL
.	NULL

Unexpectedly	NULL
,	NULL
the	NULL
transcriptional	NULL
enhancement	NULL
of	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
and	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
,	NULL
;	NULL
CAT	NULL
constructs	NULL
by	NULL
CN	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

Transcription	NULL
from	NULL
tandemly	NULL
repeated	NULL
AP-1	NULL
sequences	NULL
was	NULL
seen	NULL
to	NULL
be	NULL
stimulated	NULL
by	NULL
FK506	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PMA	NULL
/ionomycin	NULL
(	NULL
Ullman	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
may	NULL
account	NULL
for	NULL
the	NULL
failure	NULL
of	NULL
CsA	NULL
in	NULL
repression	NULL
of	NULL
the	NULL
transcriptional	NULL
enhancement	NULL
by	NULL
CN	NULL
,	NULL
since	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
strong	NULL
AP-1-binding	NULL
site	NULL
in	NULL
the	NULL
CLEO	NULL
sequence	NULL
may	NULL
become	NULL
more	NULL
dominant	NULL
than	NULL
that	NULL
of	NULL
the	NULL
weak	NULL
NF-AT-like-binding	NULL
site	NULL
when	NULL
the	NULL
CLEO	NULL
element	NULL
is	NULL
multimerized	NULL
.	NULL

There	NULL
has	NULL
been	NULL
no	NULL
direct	NULL
evidence	NULL
that	NULL
endogenous	NULL
CN	NULL
is	NULL
implicated	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
genes	NULL
through	NULL
Ca**	NULL
signaling	NULL
.	NULL

Co-transfection	NULL
experiments	NULL
can	NULL
be	NULL
done	NULL
to	NULL
determine	NULL
whether	NULL
overexpression	NULL
of	NULL
the	NULL
auto-inhibitory	NULL
domain	NULL
of	NULL
the	NULL
CNA	NULL
subunit	NULL
reduces	NULL
activation	NULL
of	NULL
these	NULL
promoters	NULL
in	NULL
response	NULL
to	NULL
PMA/A23187	NULL
,	NULL
since	NULL
a	NULL
high	NULL
dose	NULL
of	NULL
a	NULL
peptide	NULL
to	NULL
this	NULL
domain	NULL
inhibits	NULL
the	NULL
phosphatase	NULL
activity	NULL
in	NULL
vitro	NULL
(	NULL
Hashimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

A	NULL
dominant	NULL
negative	NULL
mutant	NULL
of	NULL
CNA	NULL
subunit	NULL
,	NULL
which	NULL
lacks	NULL
only	NULL
the	NULL
phosphatase	NULL
ac-tivity	NULL
,	NULL
may	NULL
also	NULL
be	NULL
useful	NULL
to	NULL
block	NULL
activation	NULL
of	NULL
endogenous	NULL
CN	NULL
in	NULL
response	NULL
to	NULL
the	NULL
Ca**	NULL
signaling	NULL
by	NULL
com-petition	NULL
.	NULL

These	NULL
strategies	NULL
,	NULL
however	NULL
,	NULL
may	NULL
not	NULL
be	NULL
feasible	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
because	NULL
at	NULL
least	NULL
two	NULL
subtypes	NULL
of	NULL
the	NULL
CN	NULL
catalytic	NULL
subunit	NULL
have	NULL
been	NULL
identified	NULL
by	NULL
molecular	NULL
cloning	NULL
(	NULL
Kincaid	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

125	NULL
A.	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

It	NULL
also	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
NF-AT	NULL
and	NULL
OCT-1/OAP-40	NULL
,	NULL
CsA	NULL
and	NULL
FK506	NULL
inhibit	NULL
,	NULL
by	NULL
~50	NULL
%	NULL
,	NULL
both	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
immunoglobulin	NULL
Â«	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
Ig-	NULL
Â«	NULL
B	NULL
)	NULL
sequence	NULL
and	NULL
the	NULL
ability	NULL
of	NULL
multimerized	NULL
Ig-	NULL
Â«	NULL
B	NULL
sequences	NULL
to	NULL
activate	NULL
expression	NULL
from	NULL
a	NULL
reporter	NULL
plasmid	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
/ionomycin	NULL
(	NULL
Emme	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Mattila	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

NF-	NULL
Â«	NULL
B	NULL
binding	NULL
is	NULL
less	NULL
sensitive	NULL
to	NULL
these	NULL
immunosuppressants	NULL
since	NULL
it	NULL
is	NULL
largely	NULL
induced	NULL
by	NULL
PMA	NULL
alone	NULL
.	NULL

The	NULL
increased	NULL
level	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
(	NULL
binding	NULL
and	NULL
transcription	NULL
)	NULL
induced	NULL
by	NULL
addition	NULL
of	NULL
ionomycin	NULL
is	NULL
completely	NULL
inhibited	NULL
by	NULL
CsA	NULL
and	NULL
FK506	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Mattila	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

We	NULL
reported	NULL
earlier	NULL
that	NULL
authentic	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
site	NULL
is	NULL
weaker	NULL
than	NULL
that	NULL
to	NULL
the	NULL
Ig-	NULL
Â«	NULL
B	NULL
sequence	NULL
(	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Since	NULL
PMA/A23187-induced	NULL
binding	NULL
to	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
site	NULL
is	NULL
inhibited	NULL
down	NULL
to	NULL
a	NULL
PMA	NULL
level	NULL
by	NULL
CsA	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
,	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
site	NULL
may	NULL
be	NULL
another	NULL
target	NULL
for	NULL
CsA	NULL
effects	NULL
;	NULL
this	NULL
contribution	NULL
,	NULL
if	NULL
any	NULL
,	NULL
would	NULL
be	NULL
less	NULL
significant	NULL
than	NULL
that	NULL
of	NULL
the	NULL
CLEO	NULL
element	NULL
.	NULL

There	NULL
are	NULL
reports	NULL
that	NULL
the	NULL
Ig-	NULL
Â«	NULL
B	NULL
and	NULL
HIV-	NULL
Â«	NULL
B	NULL
sequences	NULL
can	NULL
be	NULL
recognized	NULL
by	NULL
an	NULL
-like	NULL
,	NULL
CsA-sensitive	NULL
factor	NULL
under	NULL
certain	NULL
conditions	NULL
of	NULL
binding	NULL
reaction	NULL
or	NULL
stimulation	NULL
(	NULL
Schmidt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
McCaffrey	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

These	NULL
Â«	NULL
B	NULL
sequences	NULL
contain	NULL
GGGACTITCC	NULL
and	NULL
share	NULL
homology	NULL
with	NULL
the	NULL
above	NULL
Ets-binding	NULL
site	NULL
(	NULL
TTTCC	NULL
)	NULL
.	NULL

We	NULL
have	NULL
already	NULL
purified	NULL
NF-AT	NULL
from	NULL
nuclear	NULL
extracts	NULL
of	NULL
PMA/	NULL
A23187-stimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
Tokumitsu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
;	NULL
A	NULL
giga	NULL
--	NULL
-	NULL
--	NULL
-	NULL
Relative	NULL
CAT	NULL
activity	NULL
(	NULL
fold	NULL
induction	NULL
)	NULL
CN	NULL
A	NULL
&	NULL
B	NULL
PMAIAZ3187	NULL
-	NULL
-	NULL
+	NULL
Reporter	NULL
.	NULL

p	NULL
(	NULL
GM-xB/GC-box	NULL
)	NULL
CAT	NULL
-	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
CAT	NULL
CAT	NULL
Enc	NULL
GG	NULL
@	NULL
TAGTTCCCCCGCCCCCCT	NULL
91	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
CAT	NULL
clea	NULL
__|__	NULL
Cleg	NULL
c	NULL
A	NULL
_I	NULL
%	NULL
AGTTCTGTGGTCACCATTAATCATTTCCTCTAA	NULL
purified	NULL
NFE-AT	NULL
fails	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
sequence	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
.	NULL

However	NULL
,	NULL
certain	NULL
Â«	NULL
B	NULL
sequences	NULL
may	NULL
be	NULL
other	NULL
candidates	NULL
for	NULL
the	NULL
CsA	NULL
action	NULL
through	NULL
NF-AT	NULL
-like	NULL
proteins	NULL
.	NULL

The	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
seems	NULL
to	NULL
be	NULL
one	NULL
of	NULL
the	NULL
targets	NULL
for	NULL
the	NULL
CsA	NULL
and	NULL
CN	NULL
actions	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
,	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
Randak	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Mobility	NULL
shift	NULL
assays	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
and	NULL
co-transfection	NULL
experiments	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
suggested	NULL
that	NULL
the	NULL
GM-	NULL
Â«	NULL
B	NULL
sequence	NULL
may	NULL
be	NULL
another	NULL
target	NULL
for	NULL
the	NULL
CsA	NULL
and	NULL
CN	NULL
ef-fects	NULL
.	NULL

Transfection	NULL
experiments	NULL
using	NULL
GM-CSF	NULL
CAT	NULL
constructs	NULL
with	NULL
the	NULL
CLEO	NULL
or	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
mutation	NULL
revealed	NULL
that	NULL
cooperation	NULL
between	NULL
the	NULL
CLEO	NULL
and	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
elements	NULL
is	NULL
required	NULL
for	NULL
both	NULL
maximal	NULL
activation	NULL
of	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
and	NULL
its	NULL
enhancement	NULL
by	NULL
exogenous	NULL
CN	NULL
expression	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
an	NULL
intergenic	NULL
enhancer	NULL
,	NULL
located	NULL
between	NULL
human	NULL
GM-CSF	NULL
and	NULL
IL-3	NULL
genomic	NULL
genes	NULL
,	NULL
may	NULL
participate	NULL
in	NULL
the	NULL
inducibility	NULL
of	NULL
both	NULL
genes	NULL
and	NULL
be	NULL
a	NULL
target	NULL
for	NULL
CsA	NULL
in-hibition	NULL
.	NULL

(	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

This	NULL
enhancer	NULL
contains	NULL
four	NULL
AP-1	NULL
binding	NULL
sites	NULL
,	NULL
three	NULL
of	NULL
which	NULL
are	NULL
associated	NULL
with	NULL
an	NULL
NF-AT-like	NULL
factor	NULL
and	NULL
are	NULL
similar	NULL
to	NULL
the	NULL
CLEO	NULL
element	NULL
(	NULL
Cockerill	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

To	NULL
account	NULL
for	NULL
activation	NULL
of	NULL
the	NULL
endogenous	NULL
GM-CSF	NULL
gene	NULL
as	NULL
well	NULL
as	NULL
its	NULL
sensitivity	NULL
to	NULL
CsA	NULL
,	NULL
interaction	NULL
between	NULL
the	NULL
distal	NULL
and	NULL
prox-imal	NULL
CLEO-like	NULL
elements	NULL
should	NULL
be	NULL
also	NULL
considered	NULL
in	NULL
the	NULL
mouse	NULL
GM-CSF/IL-3	NULL
locus	NULL
.	NULL

We	NULL
have	NULL
pointed	NULL
out	NULL
that	NULL
the	NULL
CLEO	NULL
element	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
shares	NULL
ho	NULL
Reporter	NULL
CAT	NULL
CN	NULL
A	NULL
&	NULL
B	NULL
=	NULL
-	NULL
+	NULL
PMA/A23187	NULL
-	NULL
+	NULL
-	NULL
+	NULL
#	NULL
&	NULL
Y	NULL
e	NULL
Â®	NULL
Â®	NULL
Â®	NULL
Relative	NULL
activity	NULL
1	NULL
.	NULL

31	NULL
1	NULL
.	NULL

100	NULL
p	NULL
(	NULL
CLEOkCAT	NULL
Eng	NULL
Ã©ï¬CCATTAATg	NULL
QATTTQQTCTAQ	NULL
â	NULL
Figure	NULL
6	NULL
,	NULL
-	NULL
Exogenously	NULL
expressed	NULL
CN	NULL
stimulates	NULL
CLEO-dependent	NULL
transcription	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
co-transfected	NULL
either	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
,	NULL
CAT	NULL
(	NULL
A	NULL
)	NULL
,	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
(	NULL
A	NULL
)	NULL
or	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
(	NULL
C	NULL
)	NULL
along	NULL
with	NULL
either	NULL
pBJ5	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
or	NULL
pBJ5-CNA	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
pBJ5-CNB	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
,	NULL
and	NULL
divided	NULL
into	NULL
2	NULL
aliquots	NULL
.	NULL

After	NULL
24	NULL
h	NULL
incubation	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
15	NULL
h	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
and	NULL
A23187	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
as	NULL
thin	NULL
layer	NULL
chromatogram	NULL
(	NULL
C	NULL
)	NULL
,	NULL
quantitated	NULL
as	NULL
fold	NULL
induction	NULL
of	NULL
CAT	NULL
activity	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
C	NULL
)	NULL
,	NULL
and	NULL
are	NULL
the	NULL
averages	NULL
of	NULL
3	NULL
independent	NULL
experiments	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
p	NULL
(	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
)	NULL
,	NULL
CAT	NULL
(	NULL
B	NULL
)	NULL
,	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
p	NULL
(	NULL
CLEO	NULL
)	NULL
;	NULL
CAT	NULL
(	NULL
D	NULL
)	NULL
carrying	NULL
tandemly	NULL
repeated	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
or	NULL
CLEO	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
minimal	NULL
GM-CSF	NULL
promoter	NULL
(	NULL
position	NULL
-36	NULL
to	NULL
+27	NULL
)	NULL
.	NULL

Underlines	NULL
show	NULL
the	NULL
GM-	NULL
Â«	NULL
B/GC-box	NULL
and	NULL
CLEO	NULL
sequences	NULL
essential	NULL
for	NULL
binding	NULL
of	NULL
respective	NULL
factors	NULL
.	NULL

Means	NULL
and	NULL
SD	NULL
are	NULL
1	NULL
+	NULL
0.23	NULL
,	NULL
3.1	NULL
+	NULL
0.37	NULL
,	NULL
1	NULL
+	NULL
0.037	NULL
,	NULL
5.4	NULL
+	NULL
0.27	NULL
,	NULL
1	NULL
+	NULL
0.059	NULL
,	NULL
9.5	NULL
+	NULL
1.2	NULL
,	NULL
1	NULL
+	NULL
0.015	NULL
,	NULL
and	NULL
19	NULL
+	NULL
0.81	NULL
(	NULL
A	NULL
)	NULL
;	NULL
and	NULL
1	NULL
+	NULL
0.074	NULL
,	NULL
31	NULL
+	NULL
3.0	NULL
,	NULL
1	NULL
+	NULL
0.018	NULL
,	NULL
and	NULL
100	NULL
+	NULL
3.0	NULL
(	NULL
C	NULL
)	NULL
.	NULL

126	NULL
Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL
Ca	NULL
ionophore	NULL
â	NULL
A	NULL
104	NULL
95\	NULL
J	NULL
CsA	NULL
h	NULL
,	NULL
m	NULL
GM-CSF	NULL
TTPCCTC	NULL
TGAAACAAATTTTCCTCC	NULL
-	NULL
m	NULL
IL-2	NULL
ACGCCTTCTGTATCAAACAGTTTTTCCTC	NULL
'	NULL
h	NULL
IL-2	NULL
CD2BRC	NULL
APA	NULL
NF-ATÂ®	NULL
NF-AT	NULL
-	NULL
OCT*	NULL
NF-kB	NULL
APA	NULL
``	NULL
Figure	NULL
7	NULL
.	NULL

-	NULL
A	NULL
model	NULL
for	NULL
coordinated	NULL
regulation	NULL
of	NULL
the	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
genes	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
through	NULL
PMA/Ca**	NULL
inophore-respon-sive	NULL
and	NULL
CsA-sensitive	NULL
elements	NULL
,	NULL
associated	NULL
with	NULL
NF-AT	NULL
or	NULL
NF-AT-like	NULL
factor	NULL
.	NULL

NF-AT-binding	NULL
sequences	NULL
in	NULL
both	NULL
human	NULL
and	NULL
mouse	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
reverse	NULL
strand	NULL
.	NULL

Bold	NULL
letters	NULL
in	NULL
the	NULL
DNA	NULL
sequences	NULL
indicate	NULL
Ets-binding	NULL
sites	NULL
,	NULL
and	NULL
underlines	NULL
show	NULL
AP-1-like	NULL
sites	NULL
.	NULL

Asterisks	NULL
in	NULL
the	NULL
I1-2	NULL
promoter	NULL
depict	NULL
a	NULL
low-affinity	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
respective	NULL
factor	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
CD28-responsive	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
are	NULL
described	NULL
elsewhere	NULL
(	NULL
Fraser	NULL
and	NULL
Weiss	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

OCT/OAP	NULL
TATA	NULL
mology	NULL
with	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
the	NULL
IL-4	NULL
and	NULL
IL-5	NULL
genes	NULL
in	NULL
both	NULL
human	NULL
and	NULL
mouse	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

We	NULL
also	NULL
found	NULL
a	NULL
homologous	NULL
sequence	NULL
with	NULL
the	NULL
CLEO	NULL
element	NULL
in	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
the	NULL
mouse	NULL
IL-3	NULL
gene	NULL
(	NULL
AGAGCCAGGCTACTTCCTCC	NULL
)	NULL
between	NULL
positions	NULL
-262	NULL
and	NULL
-243	NULL
(	NULL
Miyatake	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

CsA	NULL
blocks	NULL
production	NULL
of	NULL
GM-CSF	NULL
,	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-5	NULL
,	NULL
induced	NULL
by	NULL
PMA/A23187	NULL
in	NULL
the	NULL
murine	NULL
cloned	NULL
T	NULL
cells	NULL
as	NULL
described	NULL
above	NULL
(	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
assume	NULL
that	NULL
the	NULL
CLEO	NULL
-like	NULL
sequence	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
coordinated	NULL
induction	NULL
of	NULL
the	NULL
GM-CSF	NULL
,	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-5	NULL
genes	NULL
through	NULL
the	NULL
Ca**-	NULL
and	NULL
PKC-signaling	NULL
pathways	NULL
mediated	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Use	NULL
of	NULL
mouse	NULL
type	NULL
2	NULL
helper	NULL
T	NULL
cell	NULL
clones	NULL
,	NULL
which	NULL
produce	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
IL-5	NULL
,	NULL
and	NULL
GM-CSF	NULL
will	NULL
facilitate	NULL
testing	NULL
as	NULL
to	NULL
whether	NULL
CN	NULL
or	NULL
CsA	NULL
affects	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
through	NULL
the	NULL
CLEO-like	NULL
sequence	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

N.A	NULL
.	NULL

Clipstone	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
for	NULL
providing	NULL
pIL-2	NULL
CAT-1	NULL
and	NULL
CN-expression	NULL
vectors	NULL
(	NULL
pBJS-CNA	NULL
,	NULL
pBJ5-CNAA	NULL
,	NULL
and	NULL
pBJ5-CNB	NULL
)	NULL
and	NULL
for	NULL
helpful	NULL
discussion	NULL
.	NULL

We	NULL
are	NULL
also	NULL
grateful	NULL
to	NULL
Dr.	NULL
P.	NULL
Berg	NULL
for	NULL
providing	NULL
Jurkat	NULL
cells	NULL
,	NULL
to	NULL
D.	NULL
Robison	NULL
for	NULL
oligonucleotide	NULL
syn-thesis	NULL
,	NULL
K.	NULL
Conger	NULL
for	NULL
plasmid	NULL
construction	NULL
,	NULL
and	NULL
Drs	NULL
.	NULL

Y.	NULL
Kaziro	NULL
,	NULL
D.	NULL
Wylie	NULL
and	NULL
M.	NULL
Muramatsu	NULL
,	NULL
and	NULL
M.	NULL
Ohara	NULL
for	NULL
critical	NULL
readings	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

DNAX	NULL
Research	NULL
Institute	NULL
of	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
is	NULL
supported	NULL
by	NULL
Schering-Plough	NULL
Corporation	NULL
.	NULL

REFERENCES	NULL
Abrams	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Roncarolo	NULL
,	NULL
M.-G.	NULL
,	NULL
Yssel	NULL
,	NULL
H.	NULL
,	NULL
Andersson	NULL
,	NULL
U.	NULL
,	NULL
Gleich	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
and	NULL
Silver	NULL
,	NULL
J.E	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Strategies	NULL
of	NULL
anti-cytokine	NULL
monoclonal	NULL
antibody	NULL
Vol	NULL
.	NULL

5	NULL
,	NULL
January	NULL
1994	NULL
Activation	NULL
of	NULL
GM-CSF	NULL
Gene	NULL
by	NULL
Calcineurin	NULL
development	NULL
:	NULL
immunoassay	NULL
of	NULL
IL-10	NULL
and	NULL
IL-5	NULL
in	NULL
clinical	NULL
samples	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

127	NULL
,	NULL
5-24	NULL
.	NULL

Arai	NULL
,	NULL
K.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
Miyajima	NULL
,	NULL
A.	NULL
,	NULL
Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Arai	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Yokota	NULL
,	NULL
T.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Cytokines	NULL
:	NULL
coordinators	NULL
of	NULL
immune	NULL
and	NULL
inflammatory	NULL
re-sponses	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

59	NULL
,	NULL
783-836	NULL
.	NULL

Arai	NULL
,	NULL
N.	NULL
,	NULL
Naito	NULL
,	NULL
Y.	NULL
,	NULL
Watanabe	NULL
,	NULL
M.	NULL
,	NULL
Masuda	NULL
,	NULL
E.S	NULL
.	NULL

,	NULL
Yamaguchi-Iwai	NULL
,	NULL
Y.	NULL
,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Heike	NULL
,	NULL
T.	NULL
,	NULL
Matsuda	NULL
,	NULL
I.	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Koyano-Nakagawa	NULL
,	NULL
N.	NULL
,	NULL
Lee	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
Muramatsu	NULL
,	NULL
M.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
lymphokine	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
:	NULL
role	NULL
of	NULL
cis-acting	NULL
DNA	NULL
elements	NULL
that	NULL
respond	NULL
to	NULL
T	NULL
cell	NULL
activation	NULL
signals	NULL
.	NULL

Pharmacol	NULL
.	NULL

Ther	NULL
.	NULL

55	NULL
,	NULL
303-318	NULL
.	NULL

Berridge	NULL
,	NULL
M.J.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Inositol	NULL
triphosphate	NULL
and	NULL
calcium	NULL
signalling	NULL
.	NULL

Nature	NULL
361	NULL
,	NULL
315-325	NULL
.	NULL

Boise	NULL
,	NULL
LH	NULL
.	NULL

,	NULL
Petryniak	NULL
,	NULL
B.	NULL
,	NULL
Mao	NULL
,	NULL
X.	NULL
,	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Wang	NULL
,	NULL
C.-Y	NULL
.	NULL

,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Bravo	NULL
,	NULL
R.	NULL
,	NULL
Kovary	NULL
,	NULL
K.	NULL
,	NULL
Leiden	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
NF-AT	NULL
DNA	NULL
binding	NULL
complex	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fra-1	NULL
and	NULL
JunB	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
1911-1919	NULL
.	NULL

Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
calcineurin	NULL
as	NULL
a	NULL
key	NULL
signalling	NULL
enzyme	NULL
in	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Nature	NULL
357	NULL
,	NULL
695-697	NULL
.	NULL

Cockerill	NULL
,	NULL
P.N	NULL
.	NULL

,	NULL
Sannon	NULL
,	NULL
MF	NULL
.	NULL

,	NULL
Bert	NULL
,	NULL
A.G.	NULL
,	NULL
Ryan	NULL
,	NULL
G.R	NULL
.	NULL

,	NULL
and	NULL
Vadas	NULL
,	NULL
M.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor/	NULL
interleukin	NULL
3	NULL
locus	NULL
is	NULL
regulated	NULL
by	NULL
an	NULL
inducible	NULL
cyclosporin	NULL
A-sensitive	NULL
enhancer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
2466-2470.	NULL
de	NULL
Wet	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Wood	NULL
,	NULL
K.V	NULL
.	NULL

,	NULL
DeLuca	NULL
,	NULL
M.	NULL
,	NULL
Helinski	NULL
,	NULL
D.R	NULL
.	NULL

,	NULL
and	NULL
Subramani	NULL
,	NULL
S.	NULL
(	NULL
1987	NULL
)	NULL
.	NULL

Firefly	NULL
luciferase	NULL
gene	NULL
:	NULL
structure	NULL
and	NULL
expression	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7	NULL
,	NULL
725-737	NULL
.	NULL

Dynan	NULL
,	NULL
W.S	NULL
.	NULL

,	NULL
and	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1983	NULL
)	NULL
.	NULL

The	NULL
promoter-specific	NULL
transcription	NULL
factor	NULL
Sp1	NULL
binds	NULL
to	NULL
upstream	NULL
sequences	NULL
in	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

Cell	NULL
35	NULL
,	NULL
79-87	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Higgins	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

Flanagan	NULL
,	NULL
W.M	NULL
.	NULL

,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Nuclear	NULL
association	NULL
of	NULL
a	NULL
T-cell	NULL
transcription	NULL
factor	NULL
blocked	NULL
by	NULL
FK-506	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Nature	NULL
352	NULL
,	NULL
803-807	NULL
.	NULL

Fraser	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
T-cell	NULL
lymphokine	NULL
gene	NULL
transcription	NULL
by	NULL
the	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4357-4363	NULL
.	NULL

Fruman	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Klee	NULL
,	NULL
C.B	NULL
.	NULL

,	NULL
Bierer	NULL
,	NULL
B.E	NULL
.	NULL

,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.I	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Calcineurin	NULL
phosphatase	NULL
activity	NULL
in	NULL
T	NULL
lymphocytes	NULL
is	NULL
inhibited	NULL
by	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
3686-3690	NULL
.	NULL

Hashimoto	NULL
,	NULL
Y.	NULL
,	NULL
Perrino	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
and	NULL
Soderling	NULL
,	NULL
T.R	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
autoinhibitory	NULL
domain	NULL
in	NULL
calcineurin	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
1924-1927	NULL
.	NULL

Heike	NULL
,	NULL
T.	NULL
,	NULL
Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Bovine	NULL
papilloma	NULL
virus	NULL
encoded	NULL
E2	NULL
protein	NULL
activates	NULL
lymphokine	NULL
genes	NULL
through	NULL
DNA	NULL
elements	NULL
,	NULL
distinct	NULL
from	NULL
the	NULL
consensus	NULL
motif	NULL
,	NULL
in	NULL
the	NULL
long	NULL
control	NULL
region	NULL
of	NULL
its	NULL
own	NULL
genome	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
1411-1417	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.G	NULL
.	NULL

,	NULL
Valge	NULL
,	NULL
A.V	NULL
.	NULL

,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
contains	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
356	NULL
,	NULL
801-804	NULL
.	NULL

Kincaid	NULL
,	NULL
RL	NULL
.	NULL

,	NULL
Gin	NULL
,	NULL
P.R	NULL
.	NULL

,	NULL
Higuchi	NULL
,	NULL
S.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Dixon	NULL
,	NULL
S.C.	NULL
,	NULL
Marietta	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
Amorese	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
and	NULL
Martin	NULL
,	NULL
B.M	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Cloning	NULL
and	NULL
characterization	NULL
of	NULL
molecular	NULL
isoforms	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
calcineurin	NULL
using	NULL
nonisotopic	NULL
methods	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
11312-11319	NULL
.	NULL

Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Higuchi	NULL
,	NULL
S.	NULL
,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Giri	NULL
,	NULL
P.R	NULL
.	NULL

,	NULL
and	NULL
Martensen	NULL
,	NULL
T.M	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
.	NULL

Structural	NULL
isoform	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
calmodulin-de-pendent	NULL
phosphoprotein	NULL
phosphatase	NULL
(	NULL
``	NULL
calcineurin	NULL
``	NULL
)	NULL
:	NULL
deriving	NULL
spec-ificity	NULL
by	NULL
linking	NULL
conserved	NULL
and	NULL
variable	NULL
regions	NULL
.	NULL

Adv	NULL
.	NULL

Prot	NULL
.	NULL

Phos-phatases	NULL
6	NULL
,	NULL
73-98	NULL
.	NULL

127	NULL
A.	NULL
Tsuboi	NULL
et	NULL
al	NULL
.	NULL

Kincaid	NULL
,	NULL
RL	NULL
.	NULL

,	NULL
Takayama	NULL
,	NULL
H.	NULL
,	NULL
Billingsley	NULL
,	NULL
ML	NULL
.	NULL

,	NULL
and	NULL
Sitkovsky	NULL
,	NULL
M.V	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
calmodulin-binding	NULL
proteins	NULL
in	NULL
B	NULL
,	NULL
T	NULL
lymphocytes	NULL
and	NULL
thymocytes	NULL
.	NULL

Nature	NULL
330	NULL
,	NULL
176-178	NULL
.	NULL

Masuda	NULL
,	NULL
E.5	NULL
.	NULL

,	NULL
Tokumitsu	NULL
,	NULL
H.	NULL
,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Shlomai	NULL
,	NULL
J.	NULL
,	NULL
Hung	NULL
,	NULL
P.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
promoter	NULL
cis-acting	NULL
element	NULL
CLEO	NULL
mediates	NULL
induction	NULL
signals	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
recognized	NULL
by	NULL
factors	NULL
related	NULL
to	NULL
AP-1	NULL
and	NULL
NEF-AT	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
7399-7407	NULL
.	NULL

Mattila	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Emmel	NULL
,	NULL
EA	NULL
.	NULL

,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

,	NULL
and	NULL
Herzenberg	NULL
,	NULL
L.A.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4425-4433	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.G	NULL
.	NULL

,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Jamieson	NULL
,	NULL
C.	NULL
,	NULL
Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

A	NULL
T	NULL
cell	NULL
nuclear	NULL
factor	NULL
resembling	NULL
NF-AT	NULL
binds	NULL
to	NULL
an	NULL
NF-	NULL
Â«	NULL
B	NULL
site	NULL
and	NULL
to	NULL
the	NULL
conserved	NULL
lymphokine	NULL
promoter	NULL
sequence	NULL
'	NULL
``	NULL
Cytokine-1	NULL
``	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
1864-1871	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.G	NULL
.	NULL

,	NULL
Perrino	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
Soderling	NULL
,	NULL
TR	NULL
.	NULL

,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

NF-ATp	NULL
,	NULL
a	NULL
T	NULL
lymphocyte	NULL
DNA-binding	NULL
protein	NULL
that	NULL
is	NULL
a	NULL
target	NULL
for	NULL
calcineurin	NULL
and	NULL
immunisuppressive	NULL
drugs	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
3747-3752	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Malefijt	NULL
,	NULL
R.D	NULL
.	NULL

,	NULL
Heike	NULL
,	NULL
T.	NULL
,	NULL
Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Takebe	NULL
,	NULL
Y.	NULL
,	NULL
Nishida	NULL
,	NULL
J.	NULL
,	NULL
Shlomai	NULL
,	NULL
J.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1988a	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cell	NULL
derived	NULL
lymphokine	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
fibroblasts	NULL
:	NULL
effects	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
p40x	NULL
protein	NULL
and	NULL
bovine	NULL
papillomavirus	NULL
encoded	NULL
E2	NULL
protein	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16	NULL
,	NULL
6547-6566	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
K.	NULL
(	NULL
1988b	NULL
)	NULL
.	NULL

T-cell	NULL
activation	NULL
signals	NULL
and	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I-encoded	NULL
p40x	NULL
protein	NULL
activate	NULL
the	NULL
mouse	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
gene	NULL
through	NULL
a	NULL
common	NULL
DNA	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
5581-5587	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Shlomai	NULL
,	NULL
J.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
mouse	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
gene	NULL
promoter	NULL
:	NULL
nuclear	NULL
factors	NULL
that	NULL
interact	NULL
with	NULL
an	NULL
element	NULL
shared	NULL
by	NULL
three	NULL
lymphokine	NULL
genes-those	NULL
for	NULL
GM-CSF	NULL
,	NULL
interleukin-4	NULL
(	NULL
IL-4	NULL
)	NULL
,	NULL
and	NULL
IL-5	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
5894-5901	NULL
.	NULL

Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Yokota	NULL
,	NULL
T.	NULL
,	NULL
Lee	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
K.	NULL
(	NULL
1985	NULL
)	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
chromosomal	NULL
gene	NULL
for	NULL
murine	NULL
interleukin-3	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83	NULL
,	NULL
316-320	NULL
.	NULL

Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
components	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cell	NULL
(	NULL
NF-AT	NULL
)	NULL
complex	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
2917-2923	NULL
.	NULL

O'Keefe	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
Tamura	NULL
,	NULL
J.	NULL
,	NULL
Kincaid	NULL
,	NULL
RL	NULL
.	NULL

,	NULL
Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
and	NULL
O'Neill	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

FK-506-	NULL
and	NULL
CsA-sensitive	NULL
activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
by	NULL
calcineurin	NULL
.	NULL

Nature	NULL
357	NULL
,	NULL
692-694	NULL
.	NULL

Randak	NULL
,	NULL
C.	NULL
,	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Hergenrother	NULL
,	NULL
M.	NULL
,	NULL
Sobotta	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
suppresses	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
binding	NULL
of	NULL
lymphocyte-specific	NULL
factors	NULL
to	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

EMBO	NULL
,	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2529-2536	NULL
.	NULL

Riegel	NULL
,	NULL
J.S	NULL
.	NULL

,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Flanagan	NULL
,	NULL
W.M	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
.	NULL

Chem	NULL
.	NULL

Immunol	NULL
.	NULL

51	NULL
,	NULL
266-298	NULL
.	NULL

128	NULL
Risse	NULL
,	NULL
G.	NULL
,	NULL
Jooss	NULL
,	NULL
K.	NULL
,	NULL
Neuberg	NULL
,	NULL
M.	NULL
,	NULL
Bruller	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
and	NULL
Muller	NULL
,	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Asymmetrical	NULL
recognition	NULL
of	NULL
the	NULL
palindromic	NULL
AP1	NULL
binding	NULL
site	NULL
(	NULL
TRE	NULL
)	NULL
by	NULL
Fos	NULL
protein	NULL
complexes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
3825-3832	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.F.	NULL
,	NULL
and	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Molecular	NULL
cloning	NULL
.	NULL

A	NULL
Laboratory	NULL
Manual	NULL
.	NULL

2nd	NULL
ed	NULL
.	NULL

,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
:	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Hennighausen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Inducible	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
Â«	NULL
B	NULL
elements	NULL
of	NULL
the	NULL
human	NULL
immunode-ficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
in	NULL
a	NULL
signal-dependent	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64	NULL
,	NULL
4037-4041	NULL
.	NULL

Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Muller	NULL
,	NULL
M.M	NULL
.	NULL

,	NULL
and	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
.	NULL

Rapid	NULL
detection	NULL
of	NULL
octamer	NULL
binding	NULL
proteins	NULL
with	NULL
``	NULL
mini-extracts	NULL
``	NULL
'	NULL
,	NULL
prepared	NULL
from	NULL
a	NULL
small	NULL
number	NULL
of	NULL
cells	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
6419	NULL
.	NULL

Schreiber	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
13	NULL
,	NULL
136-142	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Bressler	NULL
,	NULL
P.	NULL
,	NULL
Holbrook	NULL
,	NULL
N.J.	NULL
,	NULL
Norris	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Kant	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6	NULL
,	NULL
3042-3049	NULL
.	NULL

Sigal	NULL
,	NULL
N.H.	NULL
,	NULL
and	NULL
Dumont	NULL
,	NULL
FJ	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
FK-506	NULL
,	NULL
and	NULL
rapamycin	NULL
:	NULL
pharmacologic	NULL
probes	NULL
of	NULL
lymphocyte	NULL
signal	NULL
transduction	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

10	NULL
,	NULL
519-560	NULL
.	NULL

Sugimoto	NULL
,	NULL
K.	NULL
,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1990	NULL
)	NULL
.	NULL

Inducible	NULL
and	NULL
non-inducible	NULL
factors	NULL
co-operatively	NULL
activate	NULL
the	NULL
GM-CSF	NULL
promoter	NULL
by	NULL
interacting	NULL
with	NULL
two	NULL
adjacent	NULL
DNA	NULL
motifs	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

2	NULL
,	NULL
787-794	NULL
.	NULL

Takebe	NULL
,	NULL
Y.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Fujisawa	NULL
,	NULL
J.	NULL
,	NULL
Hoy	NULL
,	NULL
P.	NULL
,	NULL
Yokota	NULL
,	NULL
K.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1988	NULL
)	NULL
.	NULL

SRa	NULL
promoter	NULL
:	NULL
an	NULL
efficient	NULL
and	NULL
versatile	NULL
mammalian	NULL
cDNA	NULL
expression	NULL
system	NULL
composed	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
early	NULL
promoter	NULL
and	NULL
the	NULL
R-U5	NULL
segment	NULL
of	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
466-472	NULL
.	NULL

Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
Matkovich	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Collier	NULL
,	NULL
K.A	NULL
.	NULL

,	NULL
Kwok	NULL
,	NULL
P.	NULL
,	NULL
Dumont	NULL
,	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
S.	NULL
,	NULL
Degudicibus	NULL
,	NULL
S.	NULL
,	NULL
Siekierka	NULL
,	NULL
J.J.	NULL
,	NULL
Chin	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Hutchinson	NULL
,	NULL
N.1	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
immunosuppressant	NULL
FK506	NULL
selectively	NULL
inhibits	NULL
expression	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
718-726	NULL
.	NULL

Tokumitsu	NULL
,	NULL
H.	NULL
,	NULL
Masuda	NULL
,	NULL
ES	NULL
.	NULL

,	NULL
Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
120	NULL
kDa	NULL
component	NULL
of	NULL
the	NULL
human	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

196	NULL
,	NULL
737-744	NULL
.	NULL

Tsuboi	NULL
,	NULL
A.	NULL
,	NULL
Sugimoto	NULL
,	NULL
K.	NULL
,	NULL
Yodoi	NULL
,	NULL
J.	NULL
,	NULL
Miyatake	NULL
,	NULL
S.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
NF-GM2	NULL
that	NULL
interacts	NULL
with	NULL
a	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
GM-CSF	NULL
gene	NULL
essential	NULL
for	NULL
its	NULL
induction	NULL
in	NULL
responses	NULL
to	NULL
T-cell	NULL
activation	NULL
:	NULL
purification	NULL
from	NULL
human	NULL
T-cell	NULL
leukemia	NULL
line	NULL
Jurkat	NULL
cells	NULL
and	NULL
similarity	NULL
to	NULL
NF-	NULL
Â«	NULL
B	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

3	NULL
,	NULL
807-817	NULL
.	NULL

Uliman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

Jun	NULL
family	NULL
members	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
calcium-regulated	NULL
,	NULL
cyclosporin	NULL
A-sensitive	NULL
signaling	NULL
pathway	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
188-196	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
Northrop	NULL
,	NULL
J.P.	NULL
,	NULL
Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
421-452	NULL
.	NULL

Wasylyk	NULL
,	NULL
B.	NULL
,	NULL
Hahn	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
and	NULL
Giovane	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
.	NULL

The	NULL
Ets	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

211	NULL
,	NULL
7-18	NULL
.	NULL

Molecular	NULL
Biology	NULL
of	NULL
the	NULL
Cell	NULL

